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Abstract 
Background. Neuro-axonal injury is a hallmark of the underlying pathological processes in 
neurodegenerative disorders. Reliable quantification and longitudinal follow-up of such 
damage via a biofluid marker would be a highly relevant adjunctive tool in the treatment 
workup for patients with multiple sclerosis (MS). The neurofilament proteins have emerged as 
the first biomarker bearing promise for a clinical application beyond a research tool. For the 
first time a biomarker specifically indicative of neuronal damage can be quantified in an easily 
accessible fluid source, i.e. in serum or plasma. Second (Enzyme-linked immunosorbent assays 
(ELISA)) and third generation (electrochemiluminescence based (ECL) assays) measuring 
systems lacked sufficient sensitivity to reliably measure neurofilaments throughout the range 
of concentrations found in blood samples, and specifically failed to define normal levels. The 
single molecule array system (SIMOA) marks a qualitative technological advancement as it 
provides the sensitivity to quantify physiologic neurofilament levels. This has paved the way 
to investigate neurofilaments in a range of neurological disorders, and specifically in diseases 
with smoldering course of neurodegeneration. 
Objective. We aimed to develop and validate a highly sensitive SIMOA assay for the 
neurofilament light chain (NfL). Using this assay, we investigated blood-based neurofilament 
light chain (NfL) as fluid biomarker of disease activity, treatment response, and as a predictor 
of the long-term course of disability and morphological features of neurodegeneration in MS. 
Further, we are evaluating in a third work stream the validity of NfL as a tool to detect 
suboptimal treatment with current standard MS therapies. 
Methods.  In the first study, we quantified serum NfL (sNfL) in two independent MS patient 
cohorts: (i) in a cross-sectional cohort (142 patients) NfL in serum and CSF was correlated with 
magnetic resonance imaging (MRI) data, ii) in a longitudinal cohort (246 patients) from the 
Swiss MS Cohort study (SMSC) NfL levels in two samples post-switch to a new disease 
modifying treatment were compared to pre-switch levels and with those from 254 healthy 
controls from the Genome-Wide Association Study of Multiple Sclerosis (GeneMSA).  
In the second study, we quantified yearly serum sNfL in 259 MS patients followed up in the 
GeneMSA study for up to 10 years and 259 healthy controls who had also a one year follow up 
blood sampling.  
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Results and interpretation. NfL levels in CSF and blood were highly correlated, thus 
supporting the concept that serum is a valid biofluid source to determine accurately neuronal 
damage within the central nervous system compartment. sNfL levels were higher in relapsing 
and progressive forms of MS, compared to healthy controls and were associated with current 
clinical and MRI disease activity. Finally, sNfL levels independently predicted future disability 
worsening, and cranial and spinal cord volume loss.  
Conclusion. Our data demonstrate that NfL can be reliably quantified in peripheral blood and 
CSF. Levels are associated with a) concurrent clinical and MRI measures of acute and chronic 
disease activity, b) response to DMT and c) long-term course of disability. This supports the 
potential of sNfL to become the first precision medicine tool to monitor subclinical disease 
activity and suboptimal treatment response. 
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Zusammenfassung 
Hintergrund. Neuroaxonale Schädigung spielt bei verschiedensten neurologischen und 
neurodegenerativen Erkrankungen eine wichtige Rolle. Die Multiple Sklerose (MS) ist eine 
sehr heterogen verlaufende Erkrankung, so dass gerade hier eine verlässliche und longitudinale 
Messung dieser Schädigungen zur Beurteilung der Krankheitsaktivität, Überwachung der 
Behandlungswirksamkeit und prognostischen Einschätzung sehr wichtig wäre. Neurofilament 
Proteine, die unabhängig von ursächlichen Mechanismen neuroaxonale Schädigung anzeigen 
sind hier erstmals vielversprechende Kandidaten: im Zusammenhang mit neuroaxonaler 
Schädigung kommt es zu deren Anstiegen im Liquor, aber darüber hinaus auch im Blut. 
Enzyme-linked immunosorbent assays (ELISAs) und Elekktrochemilumineszenz basierte 
Nachweisverfahren sind von begrenzter Sensitivität. Im Gegensatz dazu erlauben neue „single 
molecule array“ (SIMOA) Detektionsverfahren die zuverlässige Messung von Neurofilamenten 
auch in Blutproben, insbesondere auch von gesunden Kontrollpersonen. Diese wichtige 
technologische Weiterentwicklung erlaubt nun die longitudinale Messung von 
Neurofilamenten bei einer Reihe von vor allem auch chronischen neuroinflammatorischen oder 
neurodegenerativen Erkrankungen. 
Ziele. Ein wichtiges Ziel dieser Arbeit war es ein hochsensitives SIMOA basiertes 
Nachweisverfahren für die leichte Kette der Neurofilamente (NfL) zu entwickeln, zu 
optimieren und zu validieren. Weitere Ziele waren es dann mit Hilfe dieses entwickelten 
Testsystems die Wertigkeit der Konzentrationen von NfL in Serumproben (sNfL) als Mass der 
Krankheitsaktivität, des Therapieansprechens, der Prognose der Behinderungsentwicklung und 
morphologischer Veränderungen im MRI zu untersuchen. 
Methoden. In der ersten Studie hatten wir Zugang zu Serumproben zur Bestimmung von NfL 
von zwei unabhängigen Studienkollektiven: i) von 142 MS Patienten mit gepaarten 
Serum/Liquorproben und Magnetresonanztomographie (MRI) Daten, ii) von 246 MS Patienten 
der Schweizerischen MS Kohorten Studie (SMSC) mit jeweils zwei Proben nach Umstellung 
bzw. Beginn einer immunmodulierenden Therapie und einer Probe vor der Umstellung und 254 
gesunde Kontrollpersonen aus der Genome-Wide Association Study of Multiple Sclerosis 
(GeneMSA). In Rahmen der zweiten Studie haben wir jährlich sNfL bei 259 MS-Patienten, die 
im Rahmen der GeneMSA-Studie bis zu 10 Jahre nachuntersucht wurden, und 259 gesunden 
Kontrollen quantifiziert.  
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Resultate. Es zeigte sich ein starker Zusammenhang zwischen den gemessenen Liquor und 
Serum NfL Konzentrationen. Diese Korrelation unterstützt die Wertigkeit von NfL Messungen 
im Blut zur Quantifizierung neuroaxonaler Schädigung innerhalb des zentralen Nervensystems. 
Sowohl schubförmige als auch progrediente MS Patienten wiesen im Vergleich zu gesunden 
Kontrollen höhere sNfL Spiegel auf, und höhere sNfL Konzentrationen waren mit aktueller 
klinischer und bildgebender Krankheitsaktivität assoziiert. Zusätzlich waren erhöhte sNfL 
Spiegel signifikant und unabhängig mit zukünftiger Behinderungszunahme und Hirn- und 
Rückenmarksatrophie assoziiert. 
Schlussfolgerungen. Zusammenfassend zeigen unsere Daten, dass NfL im peripheren Blut und 
Liquor zuverlässig quantifiziert werden kann. Erhöhte Werte sind mit a) akuten und 
chronischen klinischen und bildgebenden Massen der MS Krankheitsaktivität, b) der 
Therapieantwort und c) der Behinderungsentwicklung assoziiert. Unsere Daten unterstützen 
den möglichen Nutzen von individuellen sNfL Bestimmungen zur Detektion subklinischer 
Krankheitsaktivität und suboptimalen Therapieansprechens. 
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Chapter 1: Introduction 
1.1 A biomarker approach to MS 
A. The need for a reliable blood based biomarker in multiple sclerosis 
Multiple sclerosis (MS) is an inflammatory and neurodegenerative disease of the central 
nervous system (CNS) of unknown aetiology. Response to therapy and short, but especially 
long-term course are not predictable as current disease measures are not sufficiently precise and 
accurate to predict the course of disease in individual patients. The inability to accurately 
quantify acute and chronic clinical worsening may be an important reason for a series of failures 
in the development of neuroprotective treatments for MS. Biofluid markers bear the advantage 
of measuring ongoing pathologic changes real-time and being specific for molecular 
mechanisms of disease. Such a biomarker would be helpful in monitoring ongoing damage and 
potential treatment across all forms and stages of MS. 
Currently, oligoclonal bands and to a lesser extent the IgG-index are the only biofluid markers 
that play a role in the diagnostic workup for MS1. However, these measures are relatively 
insensitive to change over time and there is no monitoring biomarker established for MS where 
change reflects disease activity and treatment response. Monitoring biomarkers imply a 
longitudinal assessment, which could be implemented on the basis of cerebrospinal fluid (CSF) 
analysis for neu NfL2. Due to their invasiveness, sequential lumbar punctures are however 
impractical outside of research settings. Hence, the profile of a biomarker for use in routine 
clinical practice requires a) easy accessibility of fluid source for sequential measurements, i.e. 
blood or urine, b) more dynamic change over time in function of disease activity than current 
clinical and magnetic resonance imaging (MRI) measures, and c) reliable quantification vis-à-
vis its physiological levels. This PhD thesis focuses on the development of a high sensitivity 
assay for NfL and its validation as the first biomarker that may fulfill all these three premises. 
 
1.2 Neurofilaments 
There is increasing evidence that neuronal degeneration is the key factor in the pathogenesis of 
sustained neurological disability in MS and hence may be the main driver for what we call 
'disease progression' (disability worsening independent of relapse)3. Neuronal degeneration is 
seen in acute and chronic MS lesions, as well as in extralesional gray and white matter4. 
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Neurofilaments (Nf) are a family proteins that are present exclusively in neuro-axonal 
structures5. Their main role is to stabilise axon caliber of myelinated axons and consequently 
their conduction velocity6. Nf belong to the class IV intermediate filaments comprising in the 
nervous system: α-internexin, peripherin, neurofilament light (NfL; 60–70 kDa), medium 
(NfM, 130–170 kDa), and heavy chain (NfH; 180–200 kDa), Figure 1. NF are obligate 
heteropolymers composed of the NFL, NFM and NFH subunits with a subunit stoichiometry of 
4:2:15. This ratio varies during neuronal development7 and likely in neurodegenerative 
disorders like amyotrophic lateral sclerosis8. NfL is the most abundant Nf protein and acts as 
the backbone to which other Nf chains bind to. Because Nf are exclusive products of neuronal 
cells, their key advantage over other biomarkers is their specificity in terms of cellular source, 
reflection of pathomechanism and hence signal interpretation, i.e. they are highly specific for 
neuronal cell damage and eventual neuronal cell death.  
 
 
Figure 1. Structure of Neurofilaments. Domain structure and post-translational modifications 
of neurofilament subunits. Neurofilament light chain (NfL), neurofilament medium chain 
(NfM), neurofilament heavy chain (NfH), α-internexin and peripherin are the subunits of 
neurofilaments in the mature nervous system. All neurofilament subunits include a conserved 
α-helical rod domain that comprises several coiled coils, and variable amino-terminal globular 
head regions and carboxy-terminal tail domains. NfM and NfH subunits are unique among the 
intermediate filament proteins in that they have long carboxy-terminal domains with multiple 
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Lys–Ser–Pro repeats that are heavily phosphorylated. Phosphorylation and O-linked 
glycosylation sites on neurofilament subunits are shown2. 
 
1.3 Neurofilament light chain as biomarker in multiple sclerosis 
A.  Evidence from NfL measurements in cerebrospinal fluid 
The advent of the first Enzyme-linked immunosorbent assay (ELISA) detecting NfL, allowed 
its reliable quantification in CSF. Several studies showed a positive association between CSF 
NfL levels and degree of disability, clinical and MRI disease activity9-15. Further studies 
highlighted the predictive value of CSF NfL in patients with a clinically isolated syndrome for 
conversion to clinically definite MS10,12. An early indication of the role of NfL as treatment 
response biomarker came from a longitudinal study showing a decrease of NfL levels over 6-
12 months in 92 MS patients treated with natalizumab16. Similar findings could be reproduced 
in observational as well as in placebo-control settings for relapsing remitting MS (RRMS) 
treated with fingolimod13,14,17 (Figure 2) and progressive MS patients treated with 
natalizumab18, mitoxantrone and rituximab19. 
 
 
Figure 2. Neurofilament light chain levels at baseline and after 12 months. NfL levels at 
baseline (A); pooled fingolimod0.5/1.25mg: 652pg/ml; placebo: 886pg/ml, p=0.481. At 12 
months (B); NfL levels pooled fingolimod group: 335pg/ml; placebo: 738pg/ml, p=0.022. 
*Mann-Whitney test.**Sign test: baseline vs month 12. Dots represent individual samples. Box 
and whiskers plotted according to theTukey method17. 
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B.  Previous evidence from NfL measurements in serum and plasma 
The need for an easily accessible biomarker led to further efforts towards a quantification of 
NfL in serum or plasma samples and the consequent development of more sensitive 
immunoassays. In 2013 my group developed an electrochemiluminescence (ECL) based 
immunoassay20. Despite a suboptimal sensitivity to quantify serum NfL (sNfL, 18%21 and 
27%22 of samples were below detection limit), we detected that NfL levels in serum were highly 
correlated to levels in corresponding CSF samples (r = 0.62, p = 0.0002). Also, concentrations 
in serum were higher in MS patients than in healthy controls and levels correlated with white 
matter lesion volume (r = 0.68, p < 0.0001), mean T1 (r = 0.40, p = 0.034) and T2* relaxation 
time (r = 0.49, p = 0.007) and with magnetization transfer ratio in normal appearing white 
matter (r = -0.41, p = 0.029)22. In a follow-up study again using the ECL NfL assay, changes in 
sNfL were correlated with Expanded Disability Status Scale (EDSS) change (p = 0.009), and 
brain volume decreased more rapidly in patients with high baseline sNfL values (p = 0.05 at 12 
months and p = 0.008 at 24 months), while higher and increasing sNfL predicted the occurrence 
of higher numbers of gadolinium-enhancing lesions (p < 0.001 for both)21. 
Based on these findings we initiated the development and validation of a more sensitive NfL 
assay on the so called single molecule array (SIMOA) platform23. The SIMOA technology is 
based on the simultaneous counting of a large number (n=500 000 per sample)23 of single 
capture microbeads in very small reaction volumes (40 femtoliters)23,24. In contrast to 
conventional ELISA where the enzyme-substrate reaction is conducted in relatively large 
volumes (50–100 μL), SIMOA restricts the diffusion of the fluorescent molecules by femtoliter-
sized wells that can be counted with a camera simultaneously in thousands of microwells. The 
counting of active and inactive wells constitutes a digital signal corresponding to the presence 
or absence of single enzyme molecules. The resulting gain in sensitivity permits the use of low 
quantities of labeling reagent, which lowers nonspecific interactions and increases signal to 
background ratios23,25. In collaboration with colleagues in Gothenburg and applying the 
SIMOA NfL assay this group had developed,26 we found the SIMOA platform to be 126- and 
25-fold more sensitive than ELISA and our ECL assay, respectively, to quantify NfL25. 
Correlations between paired CSF and serum samples were strongest for SIMOA (r=0.88, 
p<0.001) and the ECL assay (r=0.78, p<0.001), but only moderate for the ELISA measurements 
(r=0.38, p=0.030), Figure 325. SIMOA allowed the reliable detection of NfL in all serum 
samples. In contrast, more than 50% of the samples were not reliably quantifiable by the ECL 
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assay and ELISA. Serum levels of NfL are 50-100-fold lower in serum compared to CSF. Note 
that serum levels in Figure 3 A, B, G, H, I are assigned to a calculated lower limit of 
quantification, as the actual levels cannot be quantified. This leads to an artificial vertical or 
horizontal line for serum values below this limit. Only with the SIMOA technology lower range 
NfL values can quantified (Figure 3 C, F, I), allowing a continuation of the correlation of 
serum and CSF values in these low concentrations. 
 
 
Figure 3. CSF and serum NfL correlation in different assays (A–C), associations between NfL 
measurements on different platforms in CSF (D–F) and serum (G–I). Correlations between 
paired CSF and serum samples were strongest for SIMOA (r = 0.88, p < 0.001, Figure 1C), 
and the ECL assay (r = 0.78,p < 0.001, Figure 1B). This was less clear for the ELISA 
measurements (r = 0.38, p = 0.030, Figure 1A). CSF NfL measurements on the three different 
platforms were highly correlated: ELISA-ECL: r = 1.0, p < 0.001, Figure 1D; ELISA-SIMOA 
assay: r = 1.0, p < 0.001, Figure 1E; and ECL assay -SIMOA: r = 1.0, p < 0.001, Figure 1F. 
For serum measurements, NfL levels were highly correlated between ECL assay and SIMOA (r 
= 0.86,p < 0.001, Figure 1I), whereas this relation was weaker for ELISA-ECL assay (r = 0.41, 
p = 0.018, Figure 1G) and ELISA-SIMOA (r = 0.43, p = 0.013, Figure 1H)25. 
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Chapter 2: Research objectives 
The urgent need for a biomarker able to monitor neuro-axonal injury in a disease with very 
variable course like MS motivated us in pursuing the development, analytical and clinical 
validation of NfL measurements in peripheral blood samples. Important prerequisites were our 
group’s previous experience in assay development and the access to a wide collection of CSF, 
serum and plasma samples from our department’s CSF bank and high quality observational 
studies including longitudinal biosampling. 
 
We aimed to develop an immunoassay on the SIMOA platform with high sensitivity, and 
proven parallelism, spiking and dilution linearity for the detection of NfL in blood samples. 
 
Using this assay we investigated: 
a) the association between blood and CSF NfL levels (chapter 3.1); 
b) sNfL levels in a large collection of healthy controls and explore their association with 
demographical characteristics like sex and age (chapters 3.1, 3.2) 
c) sNfL’s association with current clinical and MRI measures of disease activity in MS 
(chapters 3.1, 3.2)  
d) if sNfL could predict future clinical disease activity (chapters 3.1, 3.2) 
e) if sNfL levels predict future brain and spinal cord volume changes (chapter 3.2) 
f) the effect of disease modifying treatment (DMT) on sNfL levels (chapters 3.1) 
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Chapter 3: Publications 
 
3.1 Serum Neurofilament Light: A Biomarker of Neuronal Damage in Multiple Sclerosis 
 
 
 
Note: This publication was awarded with the Neurowind prize 2017 and the Franco Regli prize 2017. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This is a pre-copyedited, author-produced version of an article accepted for publication in Annals of 
Neurology following peer review. The version of record Disanto G*, Barro C*, Benkert P*, Naegelin 
Y, Schaedelin S, Giardiello A, Zecca C, Blennow K, Zetterberg H, Leppert D, Kappos L, Gobbi C, 
Kuhle J; Swiss Multiple Sclerosis Cohort Study Group: Serum Neurofilament light: A biomarker of 
neuronal damage in multiple sclerosis. Ann Neurol, 2017. 81(6):857-870 is available online at: 
https://onlinelibrary.wiley.com/doi/full/10.1002/ana.24954 ; doi: 10.1002/ana.24954 
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ABSTRACT 
 
Objective: Neurofilament light chains (NfL) are unique to neuronal cells, are shed to the CSF and are 
detectable at low concentrations in peripheral blood. Various diseases causing neuronal damage have 
resulted in elevated CSF concentrations. We explored the value of an ultrasensitive single-molecule 
array (Simoa) serum NfL (sNfL) assay in multiple sclerosis (MS). 
Methods: sNfL levels were measured in healthy controls (HC, n=254) and two independent MS 
cohorts: (1) cross-sectional with paired serum and CSF samples (n=142), and (2) longitudinal with 
repeated serum sampling (n=246, median (IQR) follow-up 3.1 (2.0-4.0) years). We assessed their 
relation to concurrent clinical, imaging and treatment parameters and to future clinical outcomes. 
Results: sNfL levels were higher in both MS cohorts than in HC (p<0.001). We found a strong 
association between CSF NfL and sNfL (β=0.589, p<0.001). Patients with either brain or spinal (43.4 
(25.2-65.3) pg/ml) or both brain and spinal gadolinium enhancing lesions (62.5 (42.7-71.4) pg/ml) 
had higher sNfL than those without (29.6 (20.9-41.8) pg/ml; β=1.461, p=0.005 and β=1.902, p=0.002 
respectively). sNfL was independently associated with EDSS assessments (β=1.105, p<0.001) and 
presence of relapses (β=1.430, p<0.001). sNfL levels were lower under disease modifying treatment 
(β=0.818, p=0.003). Patients with sNfL levels above the 80th, 90th, 95th, 97.5th and 99th HC based 
percentiles had higher risk of relapses (97.5th percentile: IRR=1.94, 95%CI=1.21-3.10, p=0.006) and 
EDSS worsening (97.5th percentile: OR=2.41, 95%CI=1.07-5.42, p=0.034). 
Interpretation: These results support the value of sNfL as a sensitive and clinically meaningful blood 
biomarker to monitor tissue damage and the effects of therapies in MS. 
  
10 
 
INTRODUCTION 
 
The clinical course of multiple sclerosis (MS) is highly variable, ranging from rapidly reversible 
episodes of impairment to severe disability within months after disease onset. Focal inflammation, 
chronic diffuse neuronal damage and failure of repair or compensation, all contribute to the 
development of permanent disability.1 Biomarkers reflecting tissue damage and allowing to monitor 
subclinical disease activity are highly desirable for assessment of therapeutic response and prediction 
of disability in both clinical studies and management of individual patients.2 
Together with the medium and heavy subunits, neurofilament light chain (NfL) represents one of the 
scaffolding proteins of the neuronal cytoskeleton and is released in the extracellular space following 
axonal damage.3 NfL levels are increased in the cerebrospinal fluid (CSF) of MS patients as well as 
in degenerative and traumatic neurological diseases (e.g. dementia, amyotrophic lateral sclerosis and 
spinal cord injury).4-9 CSF NfL levels are further increased during relapses and are positively 
associated with MRI lesion load and disability scores in MS.10-12 Noteworthy, CSF NfL levels have 
also been shown to be a marker of treatment response in this disease.13-17 However, lumbar punctures 
are relatively invasive procedures, limiting the value of CSF NfL in routine clinical settings. 
A commercially available ELISA (UmanDiagnostics) can be used to measure CSF NfL, but is not 
recommended for blood measurements. Using an electrochemiluminescence (ECL) based assay we 
have found increased serum NfL (sNfL) concentrations in clinically isolated syndrome (CIS) and MS 
patients.11,12,18,19 However, these studies were limited by the still relatively low sensitivity of the 
assay.20 A novel single-molecule array (Simoa) assay has shown 126- and 25-fold higher sensitivity 
than the ELISA and ECL assays respectively.20,21 This high sensitivity allows a more accurate 
quantification of the low sNfL concentrations expected in healthy controls and can help to better 
differentiate abnormal from normal values. Recent studies using this assay have shown that sNfL 
levels are increased in patients suffering from acute brain damage or chronic neurodegenerative 
disorders.22-24 
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This study had several aims: I) to obtain a pilot estimate of the distribution of sNfL concentrations in 
healthy controls (HC) and to investigate the potential influence of age and gender; II) to compare 
paired sNfL and CSF NfL levels in MS patients; III) to investigate the association between sNfL and 
number of T2 and contrast enhancing lesions in brain and spinal cord; IV) to investigate the 
association between sNfL and clinical features including occurrence of relapses, worsening of 
disability and treatment status; V) to test whether elevated sNfL levels can predict later disease 
activity and disability worsening. 
 
SUBJECTS AND METHODS 
 
Clinical settings, patient selection and sample collection 
 
Lugano cohort 
A cross-sectional cohort (n=142) was recruited between 2004 and 2015 at the Neurocentre of 
Southern Switzerland (Lugano, Switzerland), where paired serum and CSF samples are prospectively 
collected and stored as part of the diagnostic workup.25 Inclusion criteria were: I) a diagnosis of CIS, 
relapsing remitting MS (RRMS), primary progressive MS (PPMS), secondary progressive MS 
(SPMS) or radiologically isolated syndrome (RIS)26; II) availability of serum and preferentially also 
paired CSF samples at time of diagnosis; III) availability of demographic and clinical data at time of 
diagnosis; IV) availability of brain and preferentially also spinal cord MR images acquired as part of 
the diagnostic workup at time of diagnosis. All brain and spinal MRI included in the analysis were 
performed with a standardized protocol and using 1.5T and 3T scanners (Siemens Sonata and Siemens 
Skyra, Erlangen, Germany).27 
 
Swiss MS Cohort Study cohort 
  
12 
 
A longitudinal cohort (n=246) was recruited between 2009 and 2016 at the Neurologic Clinic and 
Policlinic, University Hospital Basel (Switzerland) as part of the Swiss Multiple Sclerosis Cohort 
Study (SMSC), a prospective observational study in which demographic, neuroimaging and clinical 
data as well as serum samples are collected every 6 or 12 months. Standardized clinical assessments 
with functional system score and Expanded Disability Status Scale (EDSS) calculation are performed 
by certified raters (http://www.neurostatus.net/).28,29 All samples are collected within 8 days from the 
clinical visit and stored at -80°C following standardized procedures.25 Criteria for inclusion in this 
study were: I) a diagnosis of CIS, RRMS, PPMS or SPMS; II) at least 2 but preferentially 3 available 
serum samples collected at baseline and at follow-up (FU) visits 1 and 2; III) start of disease 
modifying treatment (DMT) or switch to a different DMT shortly after baseline sample and before 
first FU sample (this only for CIS and RRMS patients); IV) availability of demographic and clinical 
data at time of sample collection including information on relapses and disability scores as measured 
by standardised assessment of the EDSS. 
 
Healthy controls 
Serum samples from 254 HC were collected between 2004 and 2007 in the Neurologic clinic and 
Policlinic, University Hospital Basel, as part of the international cohort study “GeneMSA” (Genetic 
MS Associations).30 A one year FU serum sample was available for 87 HC. Inclusion criteria were 
age 18-70 years and no diagnosis of MS as well as no known cases of MS in the family. 
 
Standard Protocol Approvals, Registrations, and Patient Consents 
The study received ethical approval by independent ethics committees of the participating centres; all 
patients provided written, informed consent. The SMSC is registered with ClinicalTrials.gov 
(NCT02433028). 
 
CSF and sNfL Measurements 
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We developed and validated a Simoa NfL assay using the capture monoclonal antibody (mAB) 47:3, 
and the biotinylated detector mAB 2:1 from UmanDiagnostics (UmanDiagnostics, Umeå,  Sweden)31, 
transferred onto the Simoa platform. mAB 47:3 was buffer exchanged and diluted to 0.3 mg/ml. 4x106 
paramagnetic beads (Quanterix) were buffer exchanged and activated using 0.5 mg/ml 1-ethyl-3-(3-
dimethylaminopropyl) carbodiimide (EDAC) (Quanterix), followed by a 30 minutes incubation at 
room temperature (RT, HulaMixer®, Thermofisher, USA). During a 2 hours incubation at RT 
(HulaMixer®) the diluted capture mAB was conjugated with the washed and activated beads. 
Subsequently the beads were washed and blocked. After three washes, the conjugated beads were 
suspended and stored at 4 °C. Biotinylated mAB 2:1 was obtained from UmanDiagnostics and stored 
at 4°C pending analysis. 
The assay was run on a Simoa HD-1 instrument (Quanterix) using a 2-step Assay Neat 2.0 protocol: 
100 µl of calibrator/sample (diluent: tris buffered saline (TBS); 0.1% Tween 20; 1% milk powder; 
400 µg/ml Heteroblock (Omega Biologicals Inc., Bozeman, USA)), 25 μL conjugated beads (diluent: 
TBS; 0.1% Tween 20; 1% milk powder; 300 µg/ml Heteroblock), and 20 μL of mAB 2:1 (0.1 µg/ml; 
diluent: TBS; 0.1% Tween 20; 1% milk powder; 300 µg/ml Heteroblock) were incubated for 47 
cadences (1 cadence = 45 s). After washing, 100 μL of streptavidin conjugated β-galactosidase (150 
pM; Quanterix) was added, followed by a 7-cadence incubation and a wash. Prior to reading, 25 μL 
Resorufin β-D-galactopyranoside (Quanterix) was added. Calibrators (neat) and samples (serum: 1:4 
dilution; CSF: 1:10 dilution) were measured in duplicates. Bovine lyophilized NfL was obtained from 
UmanDiagnostics. Calibrators ranged from 0 to 2,000 pg/ml for serum and 0 to 10,000 pg/ml for CSF 
measurements. Batch prepared calibrators were stored at -80°C. 
Intra- and inter-assay variability of the assay was evaluated with 3 native serum and 3 native CSF 
samples in 22/12 consecutive runs on independent days, respectively. For serum the mean coefficients 
of variation (CVs) of duplicate determinations for concentration were 5.6% (13.3 pg/ml, sample 1), 
6.9% (22.5 pg/ml, sample 2) and 5.3% (236.5 pg/ml, sample 3). In CSF the mean intra-assay CVs 
were 2.5% (572.6 pg/ml, sample 1), 0.7% (1601.8 pg/ml, sample 2) and 3.8% (6110.2 pg/ml, sample 
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3). Inter-assay CVs for serum were 11.3% (sample 1), 9.3% (sample 2) and 6.4% (sample 3). In CSF 
inter-assay CVs were 10.1% (sample 1), 6.2% (sample 2) and 15.5% (sample 3). We used the 
concentration of the lowest calibrator fulfilling acceptance criteria [accuracy: 80%–120%, CV of 
duplicate determination ≤ 20%] as an estimate of the analytical sensitivity.32 The analytical sensitivity 
was 0.32 pg/ml. All samples produced signals above the analytical sensitivity of the assay. Few 
samples with intra-assay CVs above 20% were repeat measured. Recovery rates ((Concentration 
spiked sample-concentration native sample)/Spiked concentration*100) were tested in 4 serum and 4 
CSF samples from healthy controls spiked with 5, 50 and 200 pg/ml and 500, 2000 pg/ml of NfL, 
respectively. The mean recovery for serum after spiking was 107% and for CSF 121%. Parallelism 
and linearity of the assay for serum and CSF were confirmed by serial dilution experiments. 32 
 
Statistics 
Categorical variables were described by counts and percentages, continuous and ordinal variables by 
median and interquartile ranges (IQR). For all analyses NfL levels were log-transformed to meet the 
normal assumption. The distribution of sNfL in HC and its association with age was modelled by 
means of Generalized Additive Models for Location, Scale and Shape (GAMLSS) using a Box-Cox 
t distribution according to Rigby & Stasinopoulos 33 and cubic splines and percentile curves were 
obtained. To quantify the variability bootstrapping was applied by drawing 100 random samples from 
the HCs. From each sample the percentile curves were estimated and the final reference percentiles 
across different ages represent averages over the 100 replicates together with the bootstrap confidence 
intervals. 
In the cross-sectional Lugano cohort, linear regression models were used to investigate the 
associations with log sNfL. Linear generalized estimating equation (GEE) models were similarly used 
to investigate associations with log sNfL in the SMSC cohort with repeated measurements. In all 
linear models with log sNfL as the dependent variable, regression coefficients (denoted with “ß” 
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throughout this work) were back-transformed to the original scale and therefore reﬂect multiplicative 
effects (i.e. an estimate of 1.05 means an increase of approximately 5% in sNfL). 
In GEE models, different correlation structures were investigated and model selection was performed 
based on QIC (quasi-likelihood under the independence model criterion).34 Based on expert input and 
signals observed in the graphical analysis, several interaction terms were investigated and the final 
model was selected based on the QIC. To investigate the course of sNfL after treatment initiation, a 
linear GEE was used with time under treatment and baseline sNfL as additional covariates in the 
multivariable model thereby excluding treatment status. This analysis was performed on all samples 
after treatment start. 
Patients’ sNfL levels were finally categorized based on the percentiles derived from the HC samples. 
Clinically meaningful events (relapses, annualized relapse rate (ARR) or EDSS worsening, both 
before and after sample collection) were then tested for association with sNfL levels above vs below 
various percentile cut-offs using GEE models. These analyses were performed for the percentiles 
curves from each of the 100 bootstrap replicates. The 100 results were integrated into a final result 
using Rubin's rule. Therefore the final results not only incorporate the standard errors of the GEE 
models but also take into account the uncertainty of the reference percentile curves. EDSS worsening 
was defined as an increase in EDSS since previous SMSC visit of ≥1.5 points from an EDSS score 
of 0.0, ≥1.0 point from an EDSS score of 1.0–5.5 or ≥0.5 point from an EDSS score ≥6.0 (median 
duration between visits=6.4 (5.2 - 11.7) months). GEEs using a Poisson distribution were used to 
compare the incidence of relapses between percentile categories and calculate incidence rate ratios 
(IRR) with 95% confidence intervals (95%CI). The models were tested for overdispersion 35 and the 
null hypothesis of equidispersion was not violated in any model. As a sensitivity analysis negative 
binomial mixed effect models were used. However, these models tended to not converge further 
supporting the use of a Poisson distribution. GEE models were similarly used to model binary 
outcomes (e.g. presence vs absence of relapses and presence vs absence of EDSS increase) and 
estimate odds ratios (OR) with 95%CI. For all models, model-predicted means (marginal means) and 
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95%CI were calculated using the lsmeans-package 36 and predicted odds were converted to 
probabilities (p=odds/(1+odds)). All analyses in which NfL was used to predict past and future 
clinical events were performed on a subset of the data excluding samples within 30 days after a 
relapse. As a sensitivity analysis, all analyses were repeated using all samples (i.e. without removing 
samples shortly after a relapse) and using only the last sample at which patients were under similar 
conditions using generalized linear models (data not shown). The quality of all models was 
investigated by visually inspecting residuals and quantile-quantile plots. All analyses were conducted 
using the statistical software R.37 
 
RESULTS 
 
sNfL levels in HC 
 
Age, gender and temporal variation 
Most HC were females (n=173, 68.1%) and the median age was 44.3 (36.4-52.4) years. The median 
sNfL concentration was 22.9 (16.8-31.4) pg/ml, with no statistically significant difference between 
males and females (23.4 (17.1-32.1) vs 22.8 (16.6-30.3) pg/ml; β=1.032, 95%CI=0.910-1.171, 
p=0.622). A positive association was instead observed between sNfL and age, with a 2.2% increase 
in sNfL for each additional year (β=1.022, 95%CI=1.018-1.026, p<0.001). Accordingly, median 
serum NfL slightly increased (by 1.8%) in the 87 HC with a second serum sample after a median 
follow-up time of 367 (364-385) days (baseline: 27.3 (20.3-35.2) pg/ml; FU: 27.8 (22.1-36.3) pg/ml). 
There was no association between sNfL and storage time (β=0.959, 95%CI=0.906-1.016, p=0.157 
after age correction). 
 
Reference percentile curves 
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The distribution of sNfL across different ages was modelled by using GAMLSS (see methods). The 
resulting 80th, 90th, 95th, 97.5th and 99th sNfL percentiles are presented in table 1. 
 
Table 1: Estimated sNfL percentiles including bootstrap confidence intervals across different 
ages calculated based on sNfL from HC samples. 
Age (years) 
sNfL percentiles (pg/ml) 
80th 90th 95th 97.5th 99th 
30 20.9 
(19.3-22.4) 
24.3 
(22.3-26.3) 
27.9 
(25.1-30.4) 
31.6 
(27.6-35.7) 
37.2 
(30.9-44.4) 
35 23.3 
(21.9-24.9) 
27.1 
(25.3-29.2) 
31.1 
(28.6-34.0) 
35.2 
(31.7-39.6) 
41.5 
(35.8-49.4) 
40 26.0 
(24.7-27.5) 
30.3 
(28.6-32.3) 
34.7 
(31.9-37.8) 
39.3 
(35.4-44.0) 
46.3 
(40.1-54.9) 
45 29.1 
(27.7-30.7) 
33.9 
(32.2-35.9) 
38.9 
(36.1-41.9) 
44.1 
(39.8-49.2) 
51.9 
(44.8-61.5) 
50 32.7 
(31.1-34.8) 
38.1 
(35.9-40.3) 
43.6 
(40.7-47.0) 
49.5 
(44.7-55.4) 
58.3 
(50.3-69.4) 
55 36.5 
(34.2-39.2) 
42.5 
(39.7-45.4) 
48.7 
(45.4-52.5) 
55.2 
(50.4-61.6) 
65.0 
(56.2-77.3) 
60 40.5 
(37.7-44.0) 
47.2 
(43.6-51.0) 
54.0 
(49.6-58.8) 
61.3 
(55.4-68.1) 
72.1 
(62.3-85.1) 
65 44.6 
(41.0-49.1) 
52.0 
(47.3-57.1) 
59.5 
(53.4-65.8) 
67.5 
(60.0-75.9) 
79.5 
(68.2-93.4) 
70 48.8 
(44.2-54.3) 
56.9 
(51.1-63.4) 
65.1 
(57.2-73.2) 
73.9 
(64.3-84.0) 
87.0 
(73.8-102.7) 
sNfL: serum neurofilament light chain; HC: healthy control. 
 
sNfL levels in the Lugano Cohort 
Demographic and clinical variables 
Serum and paired CSF samples were available in 142 and 132 patients. The median age was 37.9 
(29.8-47.8) years and 92 (64.8%) were female. There were 48 (33.8%) CIS, 62 (43.7%) RRMS, 16 
(11.3%) PPMS, 3 (2.1%) SPMS and 13 (9.1%) RIS patients. Brain and spinal cord MRI data were 
available at time of sample collection for 142 and 124 individuals. The median time between sample 
collection and the acquisition of brain and spinal cord MRI images was 5.0 (1.0-19.5) and 13.0 (4.0-
30.0) days. 
 
Serum and CSF NfL 
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Median NfL in serum (35.9 (22.1-61.7) pg/ml) was 42-fold lower than that in CSF (1521.1 (814.1-
2888.1) pg/ml). There was a strong positive association between CSF NfL and sNfL levels, with a 
10% increase in CSF leading to a 5.9% higher sNfL (log10(sNfL) = 0.0509 + 0.589*log10(NfLCSF), 
p<0.001; Pearson’s r=0.77, 95%CI=0.69-0.83, p<0.001; figure 1A). 
 
sNfL in patients and controls and associations with MRI 
As in HC samples, sNfL was positively associated with age (β=1.015, 95%CI=1.006-1.025, p=0.002), 
but not with gender (β=1.165, 95%CI=0.911-1.489, p=0.226). There was no association between 
sNfL and storage time (β=1.030, 95%CI=0.977-1.086, p=0.274, after age correction). All remaining 
analyses were corrected by including age as a covariate in the regression models. Patients had higher 
sNfL levels than HC (β=1.914, 95%CI=1.717-2.135, p<0.001). In addition, sNfL progressively 
increased with increasing number of T2 and gadolinium enhancing (GE) lesions in both brain and 
spinal cord (table 2 and figures 1B, 1C). Median sNfL levels progressively increased from 29.6 (20.9-
41.8) pg/ml in patients with GE lesions in neither brain nor spinal cord, to 43.4 (25.2-65.3) pg/ml in 
those with GE lesions in either brain or spinal cord, to 62.5 (42.7-71.4) pg/ml in those with GE lesions 
in both brain and spinal cord (either vs neither: β=1.461, 95%CI=1.128-1.892, p=0.005; both vs 
neither: β=1.902, 95%CI=1.278-2.830, p=0.002; both vs either: β=1.302, 95%CI=0.861-1.969, 
p=0.213; table 2 and figure 1D).  
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Figure 1: A) Association between CSF NfL and sNfL levels in the Lugano cohort. A 10% increase 
in CSF NfL corresponds to an increase of approximately 5.9% in sNfL (β=0.589, p<0.001). Grey 
band: 95% confidence interval. B) Association between brain T2 lesion load and sNfL levels in the 
Lugano cohort (2-9 vs 0-1: β=1.849, p=0.001; >9 vs 0-1: β=2.524, p<0.001). C) Association between 
number of brain GE lesions and sNfL levels in the Lugano cohort (1 vs 0: β=1.077, p=0.630; 2 vs 0: 
β=1.551, p=0.024; ≥3 vs 0: β=2.138, p=0.001). D) Association between brain and spinal cord GE 
lesions and sNfL levels in the Lugano cohort (either brain or spinal vs neither: β=1.461, p=0.005; 
both brain and spinal vs neither: β=1.902, p=0.002).  
 
Table 2: sNfL concentration and associations with different clinical and MRI variables in the 
Lugano cohort. 
Variables 
median (IQR)  
/ n (%) 
sNfL (median 
(IQR)) pg/ml 
β 95%CI p 
Age (years) 37.9 (29.8-47.8) - 1.015 1.006-1.025 0.002 
Gender F 92 (64.8) 33.0 (21.5-55.3) - - - 
  
20 
 
 M 50 (35.2) 44.2 (25.7-62.4) 1.165 0.911-1.489 0.226 
Oligoclonal bands Negative 13 (9.1) 26.8 (16.8-49.6) - - - 
 Positive 129 (90.9) 36.2 (22.7-61.9) 1.114 0.740-1.676 0.606 
Brain T2 lesion 
number 
0-1 16 (11.3) 17.3 (11.1-21.8) - - - 
 2-9 61 (43.0) 30.2 (21.4-49.6) 1.849 1.283-2.666 0.001 
 >9 65 (45.7) 48.0 (30.9-69.7) 2.524 1.744-3.653 <0.001 
Brain GE lesions 0 89 (63.6) 32.7 (21.3-49.7) - - - 
 1 26 (18.6) 31.6 (22.6-55.3) 1.077 0.797-1.456 0.630 
 2 15 (10.7) 58.3 (28.4-77.0) 1.551 1.064-2.259 0.024 
 ≥3 10 (7.1) 61.6 (46.4-89.1) 2.138 1.362-3.355 0.001 
Spinal T2 lesion 
number 
0 31 (25.0) 26.4 (17.2-42.8) - - - 
 1 26 (21.0) 25.4 (18.5-42.5) 0.819 0.574-1.167 0.271 
 ≥2 67 (54.0) 44.0 (29.6-64.6) 1.332 0.992-1.788 0.059 
Spinal GE lesions 0 95 (78.5) 32.4 (21.5-53.5) - - - 
 1 26 (21.5) 49.2 (30.9-66.0) 1.467 1.091-1.974 0.013 
Brain/Spinal  
GE lesions 
Neither 63 (52.9) 29.6 (20.9-41.8) - - - 
 Either 43 (36.1) 43.4 (25.2-65.3) 1.461 1.128-1.892 0.005 
 Both 13 (10.9) 62.5 (42.7-71.4) 1.902 1.278-2.830 0.002 
sNfL: serum neurofilament light chain; IQR: interquartile range; CI: confidence interval; F: female; 
M: male; GE lesions: gadolinium enhancing lesions. Age was included as additional variable in all 
models. 
 
sNfL Levels in the SMSC 
Demographic, clinical variables and treatment switches 
Three and two serum samples were available for 227 and 19 patients, respectively (i.e. total number 
of samples=719). Most patients started or switched to a new DMT shortly after baseline sample 
(“starters”, n=212, 86.2%), while 34 (13.8%) were patients with progressive MS who were either 
untreated or on continuous DMT (“non-starters”). The median time between baseline sampling and 
DMT initiation in the starters group was 41 (5.0-93.8) days. Demographic and clinical characteristics 
are shown in table 3. 
 
Table 3: Descriptive statistics of demographic and clinical variables of the SMSC patients at 
baseline (median (IQR) or counts (percentages)). 
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Variables SMSC (n=246) SMSC starters (n=212) 
SMSC non-starters 
(n=34) 
Age (years) 42.2 (33.6-51.4) 40.6 (32.8-48.8) 54.5 (49.2-60.9) 
Gender F 162 (65.9) 151 (71.2) 11 (32.4) 
 M 84 (34.1) 61 (28.8) 23 (67.6) 
Diagnosis (at baseline) CIS 14 (5.7) 14 (6.6) 0 (0.0) 
 RRMS 185 (75.2) 185 (87.3) 0 (0.0) 
 SPMS 27 (11.0) 11 (5.2) 16 (47.1) 
 PPMS 20 (8.1) 2 (0.9) 18 (52.9) 
Disease duration (years) 7.4 (1.8-15.3) 6.6 (1.6-14.3) 15.3 (7.9-23.7) 
EDSS 3.0 (1.5-4.0) 2.5 (1.5-3.5) 4.8 (3.6-6.0) 
DMT at baseline Injectable DMTs 77 (31.3) 73 (34.4) 4 (11.8) 
 Natalizumab 22 (8.9) 22 (10.4) 0 (0.0) 
 Fingolimod 9 (3.7) 9 (4.2) 0 (0.0) 
 Azathioprine 4 (1.6) 4 (1.9) 0 (0.0) 
 Mitoxantrone 6 (2.4) 3 (1.4) 3 (8.8) 
 Dimethyl fumarate 2 (0.8) 2 (0.9) 0 (0.0) 
 Rituximab 1 (0.4) 1 (0.5) 0 (0.0) 
 Other 4 (1.6) 0 (0.0) 4 (11.8) 
 Untreated 121 (49.2) 98 (46.2) 23 (67.6) 
Switch after baseline to Fingolimod - 136 (64.2) - 
 Injectable DMTs - 39 (18.4) - 
 Natalizumab - 21 (9.9) - 
 Rituximab - 16 (7.5) - 
Baseline to first follow-up (days) 224.0 (188.0-368.0) 217.0 (183.5-365.0) 363.5 (335.2-377.2) 
Baseline to second follow-up (days) 540.0 (386.0-725.5) 511.0 (383.5-700.8) 731.0 (664.5-753.0) 
Baseline to new DMT start (days) - 41.0 (5.0-93.8) - 
SMSC starters: patients starting or switching to a new disease modifying treatment (DMT) after 
baseline sampling. SMSC non-starters: progressive MS patients who were either untreated or had not 
changed DMT. F: females; M: males; CIS: clinically isolated syndrome; RRMS: relapsing remitting 
MS; SPMS: secondary progressive MS; PPMS: primary progressive MS; EDSS: Expanded Disability 
Status Scale; DMT: Disease modifying treatment. 
 
Associations between sNfL and demographic and clinical variables 
The median sNfL level in the SMSC cohort was 29.4 (20.1-45.2) pg/ml. Several variables were tested 
for association with sNfL in all patients (n=246) (table 4). As in the HC and Lugano cohorts, sNfL 
levels were positively associated with age (β=1.018, 95%CI=1.012-1.024, p<0.001) and no gender 
association was detected (table 4). Storage time was not significantly associated with sNfL (β=1.048, 
95%CI=0.999-1.099, p=0.057 after age correction). Disease duration was also significantly 
associated with sNfL (β=1.011, 95%CI=1.003-1.018, p=0.004). However, this association 
disappeared when correcting for age (β=1.001, 95%CI=0.993-1.010, p=0.755), while the age 
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association was unchanged (β=1.016, 95%CI=1.008-1.023, p<0.001). This implies disease duration 
as a proxy for age and only the latter was therefore considered in following analyses. The age 
association was present and of similar strength in both CIS/RRMS and PPMS/SPMS patients 
(β=1.015, 95%CI=1.007-1.023, p<0.001 and β=1.015, 95%CI=1.003-1.028, p=0.016; figure 2A). 
Both groups had higher sNfL than HC, even after correcting for age (CIS/RRMS: 27.2 (19.2-57.2) 
pg/ml, β=1.418, 95%CI=1.288-1.560, p<0.001; PPMS/SPMS: 41.4 (32.1-57.2) pg/ml, β=1.620, 
95%CI=1.417-1.851, p<0.001; figure 2B). sNfL concentrations were higher in PPMS/SPMS as 
compared to CIS/RRMS (β=1.450, 95%CI=1.245-1.688, p<0.001; after correcting for age: β=1.205, 
95%CI=1.106-1.418, p=0.029). Positive associations were also found in univariable analyses 
between sNfL and EDSS (β=1.141, 95%CI=1.106-1.178, p<0.001; figure 2C), presence of a relapse 
within 60 days before sampling (β=1.563, 95%CI=1.303-1.874, p<0.001) and recent EDSS 
worsening (β=1.294, 95%CI=1.090-1.536, p=0.003). Noteworthy, sNfL levels were lower in DMT 
treated versus untreated patients (β=0.717, 95%CI=0.634-0.810, p<0.001). 
All following variables were then included in the same multivariable model: age, gender (F vs M), 
EDSS, disease course (CIS/RRMS vs PPMS/SPMS), presence of relapses within 60 days before 
sampling (yes vs no), recent EDSS worsening (yes vs no) and DMT treatment status (treated vs 
untreated). sNfL levels remained significantly associated with age, EDSS, presence of relapses within 
60 days before sampling and DMT treatment status (table 4). Disease course (CIS/RRMS versus 
PPMS/SPMS) did not survive as an independent factor. We tested potential interactions between 
variables of interest and observed that the increase in sNfL per EDSS unit increase was lower in 
PPMS/SPMS than in CIS/RRMS patients (β=1.024, 95%CI=0.952-1.101 vs β=1.133, 95%CI=1.081-
1.187, respectively; interaction p=0.021; figure 2D, supplementary table 1). 
 
Table 4: Univariable and multivariable models testing associations between age, gender, EDSS, 
disease course, recent relapses, recent EDSS worsening and DMT status and sNfL in the SMSC 
cohort. 
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Variables (samples n) sNfL pg/ml 
Univariable Multivariable 
β 95%CI p β 95%CI p 
Age (719) - 1.018 1.012-1.024 <0.001 1.012 1.005-1.019 <0.001 
Gender F (474) 29.1 (20.1-44.3) - - - - - - 
 M (245) 30.9 (20.2-48.0) 1.054 0.902-1.232 0.505 0.991 0.858-1.145 0.905 
EDSS (719) - 1.141 1.106-1.178 <0.001 1.105 1.063-1.149 <0.001 
Disease course CIS/RRMS (581) 27.2 (19.2-57.2) - - - - - - 
 PPMS/SPMS (138) 41.4 (32.1-57.2) 1.450 1.245-1.688 <0.001 0.924 0.742-1.151 0.483 
Recent relapse  
(<60 days) 
No (643) 28.9 (20.0-43.8) - - - - - - 
 Yes (76) 39.3 (25.9-60.2) 1.563 1.303-1.874 <0.001 1.430 1.156-1.768 <0.001 
Recent EDSS 
worsening 
No (615) 29.0 (20.1-43.9) - - - - - - 
 Yes (51) 38.5 (27.8-64.0) 1.294 1.090-1.536 0.003 1.119 0.962-1.303 0.146 
DMT Untreated (162) 38.0 (23.8-56.7) - - - - - - 
 DMT treated (557) 27.0 (20.1-45.2) 0.717 0.634-0.810 <0.001 0.818 0.716-0.934 0.003 
sNfL: serum neurofilament light chain; CI: confidence interval; F: female; M: male; CIS: clinically 
isolated syndrome; RRMS: relapsing-remitting multiple sclerosis; PPMS: primary progressive 
multiple sclerosis; SPMS: secondary progressive multiple sclerosis; EDSS: Expanded Disability 
Status Scale; DMT: disease modifying treatment. The number of samples for each variable is 
indicated within brackets (e.g. number of samples collected in patients being under treatment at time 
of sampling = 557, number of samples collected in patients being untreated at time of sampling = 
162). Information on age, gender, EDSS, disease course, recent relapses, and DMT treatment was 
available for 719 (100%) sampling time points. No data were available for preceding EDSS scores at 
53 (7.4%) sampling time points. 
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Figure 2: A) Association between age and sNfL levels in HC, CIS/RRMS and PPMS/SPMS patients 
from the SMSC cohort. An increase of 1 year in age corresponds to an increase of approximately 
2.2%, 1.5% and 1.5% in sNfL in the three groups, respectively. Grey band: 95% confidence interval. 
B) Serum NfL in healthy controls versus CIS/RRMS and SPMS/PPMS from the SMSC cohort. C) 
Association between EDSS and sNfL levels in the SMSC cohort. A one point EDSS increase 
corresponds to a sNfL increase of approximately 14.1%. Grey band: 95% confidence interval. D) 
Significant interaction between EDSS and disease course (CIS/RRMS vs PPMS/SPMS) in the 
association with sNfL in the SMSC (interaction β=0.904, interaction p=0.021). Grey shading: 95% 
confidence interval. 
 
Associations between sNfL and time under new treatment 
Baseline sNfL levels were higher in patients starting natalizumab (50.8 (20.8-77.0) pg/ml) and 
rituximab (51.0 (29.1-71.4, pg/ml) than those initiating fingolimod (29.8 (20.7-46.4) pg/ml) and 
injectable DMTs (28.1 (18.0-43.2) pg/ml). sNfL levels at baseline were higher in all patient groups 
as compared to HC (p<0.001 for all, figure 3). We explored the association between time under 
treatment and sNfL during FU while correcting for baseline sNfL and other covariates. After 
adjustment, time since start of new treatment in years was negatively associated with FU sNfL 
(β=0.900, 95%CI=0.830-0.976, p=0.011, figure 3, supplementary table 2). The decrease in sNfL with 
time since start of new treatment appeared similar across different DMTs, but numbers were too low 
to investigate differences further. 
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Figure 3: Baseline sNfL was higher in patients starting natalizumab (50.8 pg/ml) and rituximab (51.0 
pg/ml) than in those initiating fingolimod (29.8 pg/ml) and injectable DMTs (28.1 pg/ml). sNfL levels 
decreased in patients starting injectable DMTs, fingolimod, natalizumab or rituximab over time. 
 
Serum NfL and previous and future disease activity 
We finally investigated whether high sNfL levels were associated with past and future clinical disease 
activity (relapses and EDSS worsening). To this purpose we compared sNfL measurements from the 
SMSC against the age corrected percentile curves that were constructed based on HC samples. In 
order to have a more homogeneous population, this analysis was only performed in CIS/RRMS 
patients. Out of a total of 581 samples, 287 (49.4%) samples had sNfL values above the 80th 
percentile, 228 (39.2%) above the 90% percentile, 171 (29.4%) above the 95th percentile, 135 (23.2%) 
above the 97.5th percentile and 105 (18.1%) above the 99th percentile. The median FU time after 
sample collection was 3.1 (2.0-4.0) years. 
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Previous clinical disease activity (relapses, annualized relapse rate and EDSS worsening) 
The probability of having experienced a relapse within 60 days before sampling was increased for 
sNfL measurements above versus below the 80th, 90th, 95th, 97.5th and 99th percentiles (figure 4A, 
supplementary table 3). Patients with sNfL above the 97.5th percentile were at approximately 4.0 fold 
odds of having experienced a relapse in the previous 60 days (OR=3.89, 95%CI=2.30-6.58, p<0.001). 
The mean ARR during 1 and 2 years before sample collection was higher in patients with sNfL levels 
above these percentiles (figure 4A, supplementary table 3). The incidence of relapses 1 and 2 years 
before sample collection was approximately 1.5-2.0 times higher with sNfL levels above the 97.5th 
percentile (IRR=2.08, 95%CI=1.64-2.63, p<0.001 and IRR=1.39, 95%CI=1.18-1.64, p<0.001 
respectively).  
The probability of having experienced worsening of the EDSS within 6-12 months before sampling 
was higher in patients with sNfL values above vs below the 90th, 95th, 97.5th and 99th percentiles 
(figure 4A, supplementary table 3). Patients with sNfL above the 97.5th percentile were at more than 
4.0 fold odds of having experienced EDSS worsening in the previous 6-12 months (OR=4.36, 
95%CI=2.09-9.09, p<0.001). Notably, there was a strikingly progressive probability of having 
experienced past relapses or EDSS worsening with increasing percentile categories. 
 
Future clinical disease activity (ARR and EDSS worsening) 
The mean ARR was increased during 1 and 2 years after the collection of samples with sNfL levels 
above the 80th, 90th, 95th, 97.5th and 99th percentiles (figure 4B, supplementary table 4). The incidence 
of relapses was approximately 2.0 times higher both 1 and 2 years after the collection of samples with 
sNfL levels above the 97.5th percentile (IRR=1.94, 95%CI=1.21-3.10, p=0.006 and IRR=1.96, 
95%CI=1.22-3.15, p=0.005). The proportion of patients experiencing EDSS worsening within 12 
months after sampling gradually increased with increasing sNfL percentile category (from 6.7% for 
samples <80th percentile to approximately 15% for samples >97.5th percentile (OR=2.41, 
95%CI=1.07-5.42, p=0.034)) (figure 4B, supplementary table 4). 
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Figure 4: Model-predicted means (marginal means) and model estimates including 95% confidence 
intervals from GEE models: A) Probability of a recent relapse (within 60 days before sampling), ARR 
in the one year before sampling and probability of EDSS worsening since 6-12 months before 
sampling according to sNfL percentiles. B) ARR in the one year after sampling, ARR in the two years 
after sampling and probability of EDSS worsening within one year after sampling according to sNfL 
percentiles. 287 samples (49.4%) had sNfL values above the 80th percentile, 228 samples (39.2%) 
above the 90% percentile, 171 samples (29.4%) above the 95th percentile, 135 samples (23.2%) above 
the 97.5th percentile and 105 (18.1%) above the 99th percentile.
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DISCUSSION 
 
Several candidate biomarkers have been proposed in MS 2, but their clinical relevance remains 
uncertain and none is currently accepted as a sensitive and reliable measure to monitor disease course 
in clinical practice. In two independent cohorts of patients we provide evidence that measurement of 
sNfL has several features necessary to qualify as an urgently needed laboratory marker of neuronal 
damage in MS. sNfL levels are not only significantly higher in MS patients versus controls, they 
correlate with focal lesion presence and activity in both the brain and the spinal cord, as depicted by 
MRI but also with relevant static and dynamic clinical outcomes, i.e. previous, concurrent and future 
relapses and disability worsening. 
 
Our results confirm and expand on previous studies 20,21 showing that NfL can be reliably measured 
in serum using the Simoa technology, even at very low concentrations (down to a few pg/ml). The 
observed increase of NfL levels in serum with age seen in both HC and patient cohorts mirrors the 
age association described for CSF NfL levels,38 and it is best explained by ongoing age related 
neuronal degeneration. We did not observe a difference in sNfL between genders. The tight positive 
association between CSF and sNfL levels, highlights that serum levels closely reflect NfL release 
within the CNS as already indicated by previous studies.19,39,40 
 
Both patient cohorts included in this study had higher sNfL concentration than healthy individuals. 
This confirms what has been observed in CSF NfL studies 4,7,10-12,41-44 and the results of a single 
previous investigation of CIS patients in which sNfL levels were measured using a less sensitive ECL 
assay.18 sNfL levels were also slightly higher in the Lugano than in the SMSC samples, likely because 
the former were collected as part of the diagnostic work-up, which is frequently performed shortly 
after relapses. The close association of increased blood NfL levels with neuronal damage has been 
suggested in other neurological conditions including ALS, neurodegenerative disorders, and acute 
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brain and spinal cord injury.8,22-24,39,40 In conjunction with findings in other neurological diseases, our 
results in MS strongly suggest that increased sNfL levels reflect ongoing neuronal damage 
irrespective of the underlying pathogenic mechanism. 
 
The relation between neuronal damage and NfL concentration is also supported by the clear positive 
association between sNfL and focal inflammatory MRI lesions in both brain and spinal cord. We 
found gradually increased sNfL levels in patients with higher brain T2 and GE lesion counts. A 
similar significant association was found between sNfL and presence of spinal GE lesions and was 
most pronounced when GE lesions were present in both brain and spinal cord. Several studies have 
shown associations between CSF NfL and brain T2 and GE lesions. 7,12,45 We have also previously 
shown weak associations between sNfL (as measured by the ECL assay) and brain T2 and GE lesions 
in CIS patients 18 and in a small cohort of RRMS patients (n=29).19 Our current results confirm and 
expand these findings in a larger cohort of patients and suggest that also spinal cord damage 
contributes to increased NfL concentrations in serum. This appears relevant since spinal cord 
pathology is a key factor in the development of disability in MS.27,46 
 
We made use of the longitudinal SMSC cohort with repeated measurements to simultaneously analyse 
the association between several clinical variables and sNfL. In addition to age, both presence of a 
recent relapse and disability as measured by the EDSS were positively and independently associated 
with sNfL. This suggests sNfL levels may be related to both acute inflammatory damage and chronic 
diffuse neuronal loss leading to disability progression in its proper sense. Interestingly, the EDSS 
association was more evident in CIS/RRMS than in PPMS/SPMS patients, perhaps resembling the 
slower and gradual disability accumulation characterizing progressive MS. It may also be an 
indication that disease progression in this later stage of disease is reflecting both direct tissue damage 
and reduced/exhausted compensation capacity. 
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Of particular interest in the search for biomarkers reflecting therapeutic effects is that sNfL levels 
were significantly lower in DMT treated as compared to untreated patients, independently of all other 
variables. In CIS/RRMS patients the decrease in sNfL levels correlated inversely with longer time 
since start of DMTs independent of recent relapses. Notably, treatment effects on CSF NfL levels 
have already been shown for fingolimod, natalizumab and rituximab in MS patients.13-17,47 Although 
this study was not primarily designed to investigate treatment effects, our results suggest that DMTs 
reduce sNfL levels, supporting their value for monitoring treatment response. 
 
Patients with sNfL levels above different HC based percentiles had considerably higher risk of having 
experienced a recent relapse or EDSS worsening. sNfL measurements could therefore be used to 
indicate recent neuronal damage and this could be particularly useful in case of ‘clinically silent 
disease’ or when clinical changes are difficult to interpret. Moreover, high sNfL levels were also 
associated with a higher risk of future clinical relapses and EDSS worsening. This confirms findings 
from two relatively small studies suggesting that patients with higher CSF neurofilament levels have 
a worse long-term disease outcome.48,49 Taken together, these results support the potential use of 
sNfL as a prognostic marker of clinical disease course.  
 
Our study has some limitations. Only one single standardized high resolution MRI scan was available 
as part of the clinical diagnostic workup of the Lugano cohort and no lesion volume measurements 
were available in addition to the T2 lesion counts to test for association with sNfL. Second, the follow-
up in the SMSC cohort was relatively short and did not allow an estimate of sNfL association with 
long term disease worsening or progression. The observational study design does not allow to separate 
potential treatment effects from regression to the mean phenomena in this relatively active cohort of 
patients. The percentile curves are currently based on a limited number of HC samples (n=254) and 
we did not include information on comorbidities and vascular risk factors. This will need to be 
assessed in the future as we move to application of this measure in individual patients. Finally, 
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samples were stored in different facilities and for different storage periods, but collection procedures 
were standardized 25 and we did not observe an association between storage time and sNfL in either 
patient or control cohorts. 
 
Based on the investigation of healthy controls and two large independent samples of MS patients with 
the recently developed ultrasensitive sNfL assay, this study provides a number of important findings 
that further our understanding and support the value of sNfL levels as a biomarker of tissue damage 
in MS: I) sNfL levels can be reliably and reproducibly measured in serum samples from MS patients; 
II) in independent HC and patient cohorts sNfL levels are positively associated with age but not 
gender; III) sNfL levels closely reflect NfL concentration in the CSF of MS patients; IV) sNfL levels 
are increased in MS patients as compared to HC and positively associated with T2 and GE lesions in 
both brain and spinal cord; V) sNfL levels are increased in patients with recent relapses or worsening 
of disability, are higher with increasing EDSS scores, and decrease with increasing duration of disease 
modifying treatment; VI) sNfL levels are associated with an increased risk of future relapses and 
EDSS worsening. These findings indicate that sNfL may have a role in assessing disease severity and 
worsening, as well as in monitoring the effect of disease –modifying therapy. Before being 
implemented in clinical practice, more data and research will be needed to establish reference ranges 
in the general population and sensitivity and specificity of NfL based predictions, by using larger 
cohorts of controls, and taking into account relevant comorbidities and treatment effects. Assay 
protocols will need to be standardized and validity of the assay tested across different centres.50 
Ongoing investigations of samples obtained in the setting of prospective controlled clinical trials will 
help to further elucidate the utility of sNfL measurements in monitoring treatment effects.51 
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Supplementary Material 
Supplementary table 1 
Multivariable GEE model testing associations between several demographic and clinical variables 
including EDSS*Disease course interaction and sNfL in the SMSC cohort. 
Variables / Interactions (*) 
Multivariable 
β 95%CI p 
Age (years) 1.011 1.004-1.018 0.001 
EDSS 1.133 1.081-1.187 <0.001 
Disease course CIS/RRMS - - - 
 PPMS/SPMS 1.459 0.948-2.244 0.086 
Recent relapse (<60 days) No - - - 
 Yes 1.408 1.140-1.740 0.002 
Recent EDSS worsening No - - - 
 Yes 1.131 0.970-1.317 0.115 
DMT Untreated - - - 
 Treated 0.813 0.711-0.929 0.002 
EDSS * Disease course 0.904 0.829-0.985 0.021 
 
GEE: Generalized Estimated Equations model. sNfL: serum NfL; EDSS: Expanded Disability Status 
Scale; CIS: clinically isolated syndrome; RRMS: relapsing remitting MS; SPMS: secondary 
progressive MS; PPMS: primary progressive MS; DMT: Disease modifying treatment. 
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Supplementary table 2 
Multivariable GEE model testing associations between several demographic and clinical variables 
and sNfL in the SMSC cohort after start of new DMT. 
Variables 
Multivariable 
β 95%CI p 
Time under DMT (years) 0.900 0.830-0.976 0.011 
sNfL at baseline 1.003 1.001-1.004 0.001 
Age (years) 1.015 1.008-1.021 <0.001 
Gender F - - - 
 M 0.952 0.832-1.090 0.478 
EDSS 1.096 1.054-1.139 <0.001 
Disease course CIS/RRMS - - - 
 PPMS/SPMS 0.980 0.764-1.257 0.875 
Recent relapse (<60 days) No - - - 
 Yes 1.422 1.024-1.973 0.035 
Recent EDSS worsening No - - - 
 Yes 1.203 0.964-1.501 0.102 
 
GEE: Generalized Estimated Equations model. sNfL: serum NfL; DMT: Disease modifying 
treatment; F: female; M: male; EDSS: Expanded Disability Status Scale; CIS: clinically isolated 
syndrome; RRMS: relapsing remitting MS; SPMS: secondary progressive MS; PPMS: primary 
progressive MS. 
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Supplementary table 3 
Model-predicted means (marginal means) and model estimates including 95% confidence intervals from GEE models: Probability of a relapse 
within 60 days before sampling, ARR one and two years before sampling and probability of EDSS worsening before sampling according to 
different sNfL percentile categories.  
Percentiles 
samples n (%) with 
sNfL > percentile 
Relapses <60 days before sampling ARR 1 year before sampling* 
Above (%) Below (%) OR 95%CI p Above Below IRR 95%CI p 
80th 287 (49.4) 18.7 (14.2-24.1) 7.1 (4.6-10.6) 3.02 1.72-5.28 <0.001 0.77 (0.66-0.90) 0.41 (0.34-0.50) 1.86 1.46-2.38 <0.001 
90th 228 (39.2) 21.0 (16.0-27.0) 7.5 (5.2-10.8) 3.26 1.98-5.38 <0.001 0.85 (0.72-1.01) 0.42 (0.35-0.50 2.03 1.60-2.59 <0.001 
95th 171 (29.4) 23.8 (17.9-30.9) 8.1 (5.7-11.4) 3.56 2.16-5.88 <0.001 0.92 (0.76-1.10) 0.44 (0.38-0.52) 2.06 1.62-2.62 <0.001 
97.5th 135 (23.2) 26.6 (19.5-35.1) 8.5 (6.1-11.8) 3.89 2.30-6.58 <0.001 0.97 (0.80-1.18) 0.47 (0.40-0.55) 2.08 1.64-2.63 <0.001 
99th 105 (18.1) 29.8 (21.2-40.2) 9.0 (6.6-12.3) 4.28 2.46-7.44 <0.001 1.06 (0.84-1.33) 0.48 (0.42-0.56) 2.19 1.70-2.81 <0.001 
Percentiles 
samples n (%) with 
sNfL > percentile 
ARR 2 years before sampling* EDSS worsening since visit before sampling* 
Above Below IRR 95%CI p Above (%) Below (%) OR 95%CI p 
80th 287 (49.4) 0.64 (0.57-0.73) 0.53 (0.46-0.60) 1.23 1.06-1.42 0.007 9.1 (6.1-13.4) 3.6 (1.9-6.6) 2.72 1.23-6.02 0.014 
90th 228 (39.2) 0.68 (0.59-0.77) 0.53 (0.46-0.60) 1.28 1.11-1.49 0.001 10.7 (7.0-15.9) 3.6 (2.0-6.4) 3.23 1.48-7.04 0.003 
95th 171 (29.4) 0.70 (0.61-0.80) 0.53 (0.47-0.61) 1.31 1.13-1.51 <0.001 12.9 (8.4-19.2) 3.6 (2.1-6.3) 3.93 1.85-8.33 <0.001 
97.5th 135 (23.2) 0.74 (0.64-0.87) 0.53 (0.47-0.60) 1.39 1.18-1.64 <0.001 14.8 (9.4-22.5) 3.8 (2.3-6.3) 4.36 2.09-9.09 <0.001 
99th 105 (18.1) 0.78 (0.66-0.92) 0.54 (0.48-0.61) 1.45 1.22-1.73 <0.001 17.0 (10.4-26.5) 4.0 (2.5-6.5) 4.86 2.30-10.25 <0.001 
 
OR: odds ratios; ARR: annualized relapse rate; IRR: incidence rate ratios; 95%CI=95% confidence intervals. * Samples from patients with 
a relapse within 30 days excluded. 
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Supplementary table 4 
Model-predicted means (marginal means) and model estimates including 95% confidence intervals from GEE models: ARR one and two 
years after sampling and EDSS worsening within 1 year after sampling according to different sNfL percentiles. 
Percentiles 
samples n (%) with 
sNfL > percentile 
ARR 1 year after sampling* ARR 2 years after sampling* 
Above Below IRR 95%CI p Above Below IRR 95%CI p 
80th 287 (49.4) 0.28 (0.21-0.37) 0.17 (0.12-0.24) 1.62 1.08-2.44 0.021 0.24 (0.18-0.32) 0.14 (0.10-0.19) 1.69 1.19-2.39 0.003 
90th 228 (39.2) 0.30 (0.22-0.41) 0.18 (0.13-0.24) 1.71 1.12-2.64 0.014 0.26 (0.19-0.35) 0.14 (0.11-0.19) 1.80 1.23-2.65 0.003 
95th 171 (29.4) 0.32 (0.22-0.46) 0.18 (0.14-0.24) 1.75 1.10-2.76 0.017 0.27 (0.18-0.39) 0.16 (0.12-0.21) 1.69 1.03-2.79 0.038 
97.5th 135 (23.2) 0.36 (0.24-0.52) 0.18 (0.14-0.24) 1.94 1.21-3.10 0.006 0.30 (0.21-0.45) 0.15 (0.12-0.21) 1.96 1.22-3.15 0.005 
99th 105 (18.1) 0.40 (0.26-0.62) 0.19 (0.14-0.24) 2.15 1.29-3.60 0.003 0.33 (0.21-0.50) 0.16 (0.12-0.21) 2.03 1.26-3.27 0.004 
Percentiles 
samples n (%) with 
sNfL > percentile 
EDSS worsening within 1 year after sampling* 
 
Above (%) Below (%) OR 95%CI p 
80th 287 (49.4) 11.0 (7.3-16.3) 6.7 (3.8-11.5) 1.72 0.84-3.50 0.135 
90th 228 (39.2) 12.7 (8.1-19.3) 6.5 (3.9-10.6) 2.10 1.03-4.29 0.042 
95th 171 (29.4) 15.1 (9.4-23.4) 6.3 (3.8-10.3) 2.63 1.25-5.54 0.011 
97.5th 135 (23.2) 15.3 (8.8-25.4) 7.0 (4.4-10.9) 2.41 1.07-5.42 0.034 
99th 105 (18.1) 14.6 (7.5-26.4) 7.7 (5.0-11.6) 2.06 0.85-4.98 0.110 
 
OR: odds ratios; ARR: annualized relapse rate; IRR: incidence rate ratios; 95%CI=95% confidence intervals. *Samples from patients with a 
relapse within 30 days excluded. 
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Abstract: 
Neuro-axonal injury is a key factor in the development of permanent disability in multiple 
sclerosis. Neurofilament light chain in peripheral blood has recently emerged as a biofluid 
marker reflecting neuro-axonal damage in this disease. 
We aimed at comparing serum neurofilament light chain (sNfL) levels in multiple sclerosis and 
healthy controls, to determine their association with measures of disease activity and their 
ability to predict future clinical worsening as well as brain and spinal cord volume loss. 
Neurofilament light chain was measured by Single Molecule Array assay in 2183 serum 
samples collected as part of an ongoing cohort study from 259 multiple sclerosis patients (189 
relapsing and 70 progressive) and 259 healthy controls. Clinical assessment, serum sampling 
and magnetic resonance imaging were done annually; median follow-up time was 6.5 years. 
Brain volumes were quantified by Structural Image Evaluation using Normalization of 
Atrophy, and Structural Image Evaluation using Normalization of Atrophy, Cross-sectional, 
cervical spinal cord volumes using spinal cord image analyzer (cordial). Results were analysed 
using ordinary linear regression models and generalized estimating equation modeling. 
sNfL was higher in patients with a clinically isolated syndrome or relapsing remitting multiple 
sclerosis as well as in patients with secondary or primary progressive multiple sclerosis than in 
healthy controls (age adjusted p<0.001 for both). sNfL above the 90th percentile of healthy 
controls values was an independent predictor of Expanded Disability Status Scale worsening in 
the subsequent year (p<0.001). The probability of Expanded Disability Status Scale worsening 
gradually increased by higher sNfL percentile category. Contrast enhancing and new/enlarging 
lesions were independently associated with increased sNfL (17.8% and 4.9% increase per lesion 
respectively; p<0.001). The higher the sNfL percentile level, the more pronounced was future 
brain and cervical spinal volume loss: sNfL above the 97.5th percentile was associated with an 
additional average loss in brain volume of 1.5% (p<0.001) and spinal cord volume of 2.5% over 
five years (p=0.009). 
sNfL correlated with concurrent and future clinical and MRI measures of disease activity and 
severity. High sNfL levels were associated with both, brain and spinal cord volume loss. 
Neurofilament light chain levels are a real-time, easy to measure marker of neuro-axonal injury 
that is conceptually more comprehensive than brain magnetic resonance imaging. 
 
Keywords: neurofilament light chain, biomarker, atrophy, multiple sclerosis 
Abbreviations:  EDSS: Expanded Disability Status Scale; HC: healthy controls; sNfL: serum 
Neurofilament light chain. 
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Introduction 
Multiple sclerosis is a chronic immune-mediated disease of the CNS, leading to demyelination 
and neurodegeneration. Neuro-axonal injury represents the key morphological correlate for 
long-term disability progression (Compston and Coles 2008). Biomarkers reflecting tissue 
damage, subclinical disease activity and therapeutic response are urgently needed both for 
clinical drug development and individual therapeutic decision making for multiple sclerosis 
patients. 
Neurofilament light chain represents one of the main constituents of the neuronal cytoskeleton 
and plays an important role in axonal growth, stability and intracellular transport (Yabe et al. 
2001). Previous studies have shown that Neurofilament light chain levels in CSF are associated 
with the occurrence of MRI lesions, relapses, neurological disability and treatment status in 
multiple sclerosis (Teunissen et al. 2009a;Hakansson et al. 2017;Gunnarsson et al. 
2011;Novakova et al. 2017;Disanto et al. 2017). The advent of a more sensitive method, the 
Single Molecule Array technology (Simoa) now allows the reliable quantification of 
Neurofilament light chain in plasma or serum (Kuhle et al. 2016a;Gisslen et al. 2016). Several 
studies in multiple sclerosis and other diseases have recently demonstrated that serum and CSF 
Neurofilament light chain concentrations are highly correlated, suggesting that sNfL could 
represent a reliable blood derived biomarker of neuro-axonal injury (Kuhle et al. 
2016b;Gaiottino et al. 2013;Bacioglu et al. 2016;Weydt et al. 2016;Lu et al. 2015;Piehl et al. 
2017). In a recent study we have shown that sNfL levels (i) can be reliably measured in multiple 
sclerosis patients, (ii) closely reflect CSF Neurofilament light chain levels, (iii) are positively 
associated with MRI lesion load, (iv) increase after the occurrence of clinical relapses and (v) 
decrease after initiating a disease modifying treatment (Disanto et al. 2017). Preliminary 
findings also suggested that patients with higher sNfL levels have worse later clinical disease 
outcomes and more brain atrophy (Kuhle et al. 2017a;Disanto et al. 2017). However, in these 
studies, systematic long-term clinical and quantitative brain MRI follow-up was not available, 
and the correlation of sNfL with spinal cord atrophy was not investigated at all (Disanto et al. 
2017).  
Here, we investigate a well characterized cohort of 259 multiple sclerosis patients with long-
term MRI and clinical follow-up and 259 HC aiming at: 1) replicating in a second independent 
cohort the association of sNfL with measures of concurrent and past clinical disease activity as 
well as its ability to predict future worsening in EDSS; 2) investigating the cross-sectional 
association between sNfL and quantitative MRI measures of inflammation and degeneration; 
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3) investigating the potential of sNfL to predict short- and long-term brain and spinal cord 
volume changes. 
 
Materials and Methods 
Patients 
Patients and controls were recruited in Basel as part of a prospective multicenter study initiated 
in 2003 (Genome-Wide Association Study of Multiple Sclerosis, GeneMSA; continued as of 
2011 as Serial Unified Multicenter Multiple Sclerosis Investigation, SUMMIT) (Bove et al. 
2017;Baranzini et al. 2009). The study included patients with all clinical subtypes of the disease 
(McDonald et al. 2001;Polman et al. 2005; Lublin et al., 1996). Secondary progressive multiple 
sclerosis was defined by 6 or more months of worsening neurological disability not explained 
by clinical relapses. Primary progressive multiple sclerosis was defined both by progressive 
clinical worsening for more than 12 months from symptom onset without any relapses, and by 
abnormal cerebrospinal fluid as defined by the presence of ≥2 oligoclonal bands or an elevated 
IgG index. Our study included all 259 patients who were recruited at the Neurologic Clinic and 
Policlinic, University Hospital Basel (Switzerland) between June 2004 and October 2005 as 
part of this study. All data were collected between July 2, 2004 and February 17, 2015. All 
patients provided written informed consent and the study was approved by the local ethics 
committee. 
Procedures 
Follow-up visits were performed outside acute clinical relapses, i.e. in case patients experienced 
a relapse within the previous month, the follow-up visit was postponed by 30 days. The 
concomitant use of disease modifying therapies for multiple sclerosis was permitted. Annual 
evaluations included standardized clinical assessments with functional system score and EDSS 
calculation by certified raters (http://www.neurostatus.net/). The occurrence of relapses, 
disability worsening (as measured by the EDSS), disease modifying treatment initiation or 
interruption and disease modifying treatment related adverse events were recorded at each visit. 
Brain MRI scans were performed within one week of clinical visits. An overview of available 
time points, including serum samples and MRI data is shown in Supplementary Table 1.  
Image acquisition and data analysis 
Brain MRI scans were performed on all patients at baseline and then yearly in a 1.5 Tesla MR 
scanner (Magnetom Avanto, Siemens Helthineers, Germany) equipped with a 12-element head 
matrix coil (see supplementary material for description of cranial image acquisition and data 
analysis). Cervical spinal cord volume was analyzed by cord image analyzer (cordial) (Amann 
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et al. 2016). The segmentation was carried out over a 35 mm long spinal cord segment in the 
cranial T1-weighted scan (MPRAGE, see supplementary material), starting 27 mm below the 
cisterna pontis, which corresponds to the spinal cord volume between the Foramen magnum 
and the C2/C3 intervertebral disc.  
Serum sampling and sNfL measurements 
Serum samples were collected on the same day as the clinical visit and stored at -80°C following 
standard procedures (Teunissen et al. 2009b). sNfL in longitudinal serum samples was 
measured by Simoa assay as previously described (Disanto et al. 2017). Inter-assay coefficients 
of variation for three native serum samples were 9%, 8%, and 6% for control samples with 
mean concentrations of 13.5 pg/ml, 25.8 pg/ml, and 269.5 pg/ml, respectively. The mean intra-
assay coefficient of variation of duplicate determinations for concentration was 7.4%. Repeat 
measurements were done for few samples with intra-assay coefficient of variation above 20%. 
One sample from two patients and one HC showed a sNfL value below 1.3 pg/ml (i.e. the lower 
limit of quantification). These two patients and one HC were excluded from the analysis. 
Healthy controls 
Serum samples from 259 HC were collected in the Neurologic Clinic and Policlinic, University 
Hospital Basel, as part of the Genome-Wide Association Study of Multiple Sclerosis between 
July 2004 and April 2006 (Baranzini et al. 2009). A second serum sample one year after 
baseline was available for 226 of these HC. HC were probands or genetically unrelated friends 
and spouses of the patients. Inclusion criteria for HC included age 18-70 years and no diagnosis 
of multiple sclerosis as well as no known cases of multiple sclerosis in the family. 
Statistics 
Categorical variables are described by counts and percentages, continuous and ordinal variables 
by median and interquartile range. For all analyses with sNfL as dependent variable, sNfL levels 
were log-transformed. The distribution of sNfL in HC and its association with age was modelled 
by means of Generalized Additive Models of Location, Scale and Shape (Rigby and 
Stasinopoulos 2004) and age-dependent percentiles were derived as described recently (Disanto 
et al. 2017). To obtain an age independent measure of sNfL elevation, the patients’ sNfL levels 
were finally dichotomized into levels above or below a given percentile category using five 
cutoffs (80%, 90%, 95%, 97.5% and 99%). 
Several clinical and MRI parameters were tested for association with log sNfL using 
Generalized Estimating Equation models with an ´exchangeable’ correlation structure. 
Estimates were backtransformed to the original scale and therefore represent multiplicative 
effects on the geometric mean of sNfL and are denoted by βmult throughout this work. The Wald 
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method was used to calculate confidence intervals (95%CI). Model quality was inspected 
visually using Q-Q-plots. 
EDSS worsening was modelled using binominal Generalized Estimating Equation models and 
odds ratios were estimated (denoted by βOR). EDSS worsening was defined as an increase in 
EDSS to the subsequent visit of ≥1.5 points from an EDSS score of 0.0, ≥1.0 point from an 
EDSS score of 1.0–5.5 or ≥0.5 point from an EDSS score ≥6.0. Brain volume changes were 
measured using Structural Image Evaluation using Normalization of Atrophy. Percentage brain 
volume change at 2 and 5 years of follow-up were modelled using ordinary linear regression 
models. The estimates represent additive effects and are denoted by βadd. The percentage change 
in spinal cord volume was calculated over all available 2 and 5 year follow-up intervals (i.e. 
baseline-year 2, year 1-year 3 or baseline-year 5, year 1-year 6 etc.) and modelled using 
Generalized Estimating Equation models. 
All analyses were conducted using the statistical software R (version 3.4.1) (R Core Team. 
2016). 
 
Results 
1. sNfL levels in healthy controls and reference percentile curves 
The median age in 258 HC was 44.3 (36.3-52.4) years and 177 (68.6%) were females. The 
median sNfL level was 23.6 (18.4-31.3) pg/ml with similar values for males (23.0 (17.6-30.3) 
pg/ml) and females (24.5 (18.7-31.7) pg/ml, p=0.757). A significant increase in sNfL was 
observed with age, with a 2.2% increase in sNfL per year (estimated multiplicative effect 
βmult=1.022, 95%CI=1.018-1.026, p<0.001). Accordingly, the median sNfL level in the 226 HC 
with a second serum sample after a median follow-up time of 368 (364-386) days was 24.6 
(19.6-32.3) pg/ml (baseline: 24.4 (18.4-31.3) pg/ml). The distribution of sNfL across different 
ages was modelled by using Generalized Additive Models for Location, Scale and Shape 
(Disanto et al. 2017). The resulting 80th, 90th, 95th, 97.5th and 99th sNfL percentiles are shown 
in Supplementary Table 2 and Supplementary Figure 1. 
 
2. Association of sNfL with demographic and clinical variables in Multiple Sclerosis 
patients 
The median follow-up in 257 patients with yearly serum samples was 6.5 (2.1-9.1) years. The 
study cohort included 29 samples from 11 (4.3%) patients with a clinically isolated syndrome, 
1180 samples from 178 (69.3%) patients with relapsing remitting multiple sclerosis, 377 
samples from 54 (21.0%) patients with secondary progressive multiple sclerosis and 98 samples 
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from 14 (5.4%) patients with primary progressive multiple sclerosis summing up to 1,684 
samples. Baseline demographics and clinical characteristics are shown in Supplementary Table 
3 and disease modifying treatment received at baseline and during follow-up in Supplementary 
Figure 2. 
The median sNfL level in the multiple sclerosis patients was 32.9 (23.2-46.6) pg/ml. sNfL levels 
were significantly associated with age in both relapsing multiple sclerosis (βmult=1.016, 
95%CI=1.010-1.021, p<0.001, n=1209) and progressive multiple sclerosis (βmult=1.015, 
95%CI=1.007-1.023, p<0.001, n=475). 
Both groups, relapsing multiple sclerosis and progressive multiple sclerosis patients had higher 
sNfL than HC (relapsing multiple sclerosis: 29.7 (21.2-42.2) pg/ml and progressive multiple 
sclerosis: 41.9 (31.9-55.7) pg/ml; after age correction: βmult=1.263, 95%CI=1.179-1.353 and 
βmult=1.423, 95%CI=1.284-1.576, respectively, p<0.001 for both comparisons) (Supplementary 
Figure 3); sNfL levels were also higher in progressive multiple sclerosis as compared to 
relapsing multiple sclerosis (βmult=1.312, 95%CI=1.198-1.436, p<0.001, Supplementary Table 
4; after age correction: βmult=1.154, 95%CI=1.059-1.258, p=0.001). Progressive multiple 
sclerosis patients with (51.4 (40.9-60.2) pg/ml) versus without (40.8 (30.6-52.5) pg/ml) contrast 
enhancing lesions had higher sNfL levels, but this did not reach statistical significance 
(βmult=1.121, 95%CI=0.933-1.346, p=0.223; after age correction: βmult=1.123, 95%CI=0.932-
1.352, p=0.222). However, progressive multiple sclerosis patients without contrast enhancing 
lesions had higher sNfL levels than HC (βmult=1.691, 95%CI=1.526-1.874, p<0.001; after age 
correction: βmult=1.406, 95%CI=1.262-1.566, p<0.001). 
 
Univariable analyses showed significant positive associations of sNfL with EDSS (βmult=1.094, 
95%CI=1.070-1.120, p<0.001) as well as with presence of a relapse within 120 days before 
sampling (βmult=1.118, 95%CI=1.034-1.208, p=0.005). In a multivariable model, the 
association of higher sNfL levels with higher age, EDSS and with a recent relapse were 
confirmed, whereas higher values of progressive versus relapsing multiple sclerosis were no 
longer statistically significant. There was a trend for a positive association between being under 
treatment at time of sampling and sNfL in both univariable and multivariable models, although 
this effect was not statistically significant (Supplementary Table 4). 
 
3. Associations between sNfL and EDSS worsening in the following year 
Next, we investigated the potential of sNfL to predict EDSS worsening. sNfL levels above the 
90th percentile compared to levels below were associated with increased odds of EDSS 
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worsening at the next visit (estimated odds ratio βOR=2.577, 95%CI=1.553-4.278, p<0.001, 
n=677 observations) (Table 1). In the multivariable model sNfL above the 90th percentile 
(βOR=2.786, 95%CI=1.609-4.826, p<0.001, n=677 observations) and T2 lesion volume (βOR 
=1.061, 95%CI=1.023-1.101, p=0.001) were the only significant predictors of an EDSS 
worsening in the subsequent year (Table 1). Notably, the odds ratio and similarly the estimated 
average probability of EDSS worsening gradually increased with increasing sNfL percentile 
category (Figure 1, Supplementary Table 5). 
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Table 1. Estimated odds ratios (βOR) of EDSS worsening within the next year (univariable and multivariable GEE models testing associations between 
serum NfL, clinical and MRI variables). 
Variables 
(677 observations) 
Univariable Multivariable 
βOR 95%CI p βOR 95%CI p 
NfL>90th percentile 2.577 1.553-4.278 <0.001 2.786 1.609-4.826 <0.001 
Age at sampling (years) 1.003 0.978-1.029 0.816 1.005 0.977-1.034 0.714 
Sex 
F (439) - - - - - - 
M (238) 1.429 0.848-2.411 0.18 1.377 0.806-2.353 0.242 
EDSS 1.080 0.924-1.263 0.332 0.926 0.762-1.125 0.440 
Disease course 
RMS (502) - - - - - - 
PMS (175) 1.655 0.934-2.933 0.084 1.297 0.647-2.600 0.464 
Recent relapse  
(<120 days) 
No (611) - - - - - - 
Yes (66) 1.847 0.888-3.841 0.1 1.993 0.892-4.454 0.093 
DMT 
Untreated (181) - - - - - - 
Treated (496) 0.630 0.363-1.092 0.099 0.596 0.320-1.108 0.102 
T2 lesion vol. (per cm3) 1.053 1.020-1.086 0.001 1.061 1.023-1.101 0.001 
New/enlarging T2 0.991 0.890-1.103 0.866 0.899 0.749-1.080 0.255 
CEL 1.028 0.701-1.508 0.886 1.180 0.601-2.317 0.631 
nBV (per 100cm3) 0.861 0.663-1.118 0.262 1.109 0.779-1.577 0.567 
BL: baseline; CEL: contrast enhancing lesions; CI: confidence interval; DMT: disease modifying treatment; EDSS: Expanded Disability Status 
Scale; F: female; IQR: interquartile range; M: male; nBV: normalized brain volume; NfL: serum neurofilament light chain; PMS: progressive 
multiple sclerosis; RMS: relapsing multiple sclerosis.
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Figure 1. The estimated proportion of patients with EDSS worsening gradually increased  with 
increasing sNfL percentile category based on healthy controls (above vs. below 80th percentile: 
βOR=1.539, 95%CI=1.067-2.219, p=0.021; above vs. below 99th percentile: βOR=2.143, 
95%CI=1.274-3.606, p=0.004, n=1401 observations). The percentiles were constructed based 
on HC samples. Numbers in the figure denote the number of samples above or below the 
respective percentiles of healthy controls. 
 
4. Association of sNfL with brain MRI measures of disease activity and normalized 
brain volume 
In the univariable analysis (Table 2) sNfL was found to be associated with all established MRI 
measures and increased with increasing lesion load (see Supplementary Figure 4 for contrast 
enhancing lesions and Supplementary Figure 5 for new or enlarging T2 hyperintense lesions). 
In the multivariable model each contrast enhancing lesion was associated with a 17.8% increase 
in sNfL (βmult=1.178, 95%CI=1.078-1.287, p<0.001, n=764), and each new or enlarging T2 
hyperintense lesion with an average increase in sNfL levels by 4.9% (βmult=1.049, 
95%CI=1.031-1.067, p<0.001) (Table 2). A smaller normalized brain volume was associated 
with higher sNfL levels: sNfL was increased by 11.7% per 100cm3 reduction of normalized 
brain volume (βmult=0.883, 95%CI=0.831-0.938, p<0.001). Conversely, the relationship with 
T2 lesion volume was no longer visible in the multivariable analysis (βmult=0.996, 
95%CI=0.987-1.006, p=0.450).
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Table 2. Estimates of univariable and multivariable GEE models testing associations between sNfL and lesional and brain volume MRI variables. 
The estimates represent multiplicative effects (βmult) since the endpoint sNfL was log transformed. 
Variables 
(764 observations) 
Univariable Multivariable 
βmult 95%CI P βmult 95%CI P 
Age 1.015 1.010-1.021 <0.001 1.014 1.008-1.019 <0.001 
Sex 
F (498) - - - - - - 
M (266) 1.124 0.998-1.264 0.053 1.087 0.985-1.198 0.097 
CEL 1.314 1.195-1.445 <0.001 1.178 1.078-1.287 <0.001 
T2 lesion vol. (per cm3) 1.012 1.004-1.020 0.003 0.996 0.987-1.006 0.450 
New/enlarging T2 1.057 1.037-1.077 <0.001 1.049 1.031-1.067 <0.001 
nBV (per 100 cm3) 0.856 0.812-0.903 <0.001 0.883 0.831-0.938 <0.001 
CEL: contrast enhancing lesions; CI: confidence interval; F: female; M: male; nbV: normalized brain volume; NfL: serum neurofilament light 
chain; IQR: interquartile range.  
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5. Association of baseline sNfL with future brain volume changes  
We tested whether baseline sNfL levels were associated with brain volume changes over the 
following years. In the univariable model sNfL levels at baseline were significantly associated 
with the percentage of brain volume change over 2 years: an increase in sNfL by 10 pg/ml was 
associated with an average additional reduction in brain volume of 0.17% after 2 years (βadd=-
0.171%, 95%CI=-0.226--0.116%, p<0.001, n=197 observations). Besides a weaker signal for 
baseline EDSS in the multivariable model (βadd=-0.151, 95%CI=-0.271--0.031, p=0.014, n=197 
observations), sNfL remained the only strong predictor of brain volume change over two years 
(βadd=-0.134%, 95%CI=-0.194--0.073%, p<0.001; Supplementary Table 6), while this was not 
the case for acute and chronic lesional activity. 
Repeating the same analysis for baseline to year 5 percentage brain volume change showed 
similar results with sNfL (Figure 2, Table 3): Confirming the 2-year results, baseline sNfL was 
a highly significant predictor of percentage brain volume change over 5 years of follow-up 
(βadd=-0.287%, 95%CI=-0.432--0.142%, p<0.001, n=132) in a multivariable analysis that 
included EDSS (βadd=-0.294%, 95%CI=-0.545--0.042%, p=0.023), disease course and several 
MRI baseline variables (Table 3). 
 
Figure 2. In the univariable model sNfL levels at baseline were significantly associated with 
the percentage brain volume change over 5 years (βadd=-0.352%, 95%CI=-0.490--0.214% per 
10 pg/ml change in sNfL, p<0.001, n=132 observations), i.e. an estimated additional 0.35% 
reduction in brain volume over 5 years per 10 pg/ml increase in baseline sNfL. 
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Table 3. Estimated percentage brain volume change over 5 years (βadd) in univariable and multivariable linear models testing testing for associations 
with baseline variables. 
Baseline variables 
(132 observations) 
Univariable Multivariable 
βadd (%) 95%CI (%) P βadd (%) 95%CI (%) p 
sNfL (per 10 pg/ml) -0.352 -0.490--0.214 <0.001 -0.287 -0.432--0.142 <0.001 
Age (years) -0.025 -0.054-0.005 0.098 0.008 -0.025-0.040 0.642 
Sex 
F (87) - - - - - - 
M (45) -0.394 -1.058-0.269 0.241 -0.229 -0.845-0.387 0.463 
EDSS  -0.454 -0.654--0.255 <0.001 -0.294 -0.545--0.042 0.023 
Disease 
course 
RMS (97) - - - - - - 
PMS (35) -0.839 -1.579--0.099 0.027 0.118 -0.734-0.971 0.784 
T2 lesion vol. (per cm3) -0.064 -0.111--0.017 0.008 -0.028 -0.081-0.025 0.294 
CEL -0.259 -0.549-0.031 0.079 -0.055 -0.328-0.219 0.693 
nBV (per 100 cm3) 0.546 0.235-0.857 <0.001 0.167 -0.235-0.570 0.412 
CEL: contrast enhancing lesions; CI: confidence interval; EDSS: Expanded Disability Status Scale; F: female; IQR: interquartile range; M: male; 
sNfL: serum neurofilament light chain. 
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In addition, we compared sNfL measurements of multiple sclerosis patients against the age 
corrected percentile curves that were constructed based on HC samples. The mean percentage 
brain volume change in patients with sNfL above the respective percentiles gradually increased 
with increasing sNfL percentile category both over 2 (Figure 3A) and over 5 years (Figure 3B) 
of follow up (Supplementary Table 7). We performed the same analysis in all progressive 
multiple sclerosis patients without contrast enhancing lesions over 2 and 5 years (n=45 and 26 
observations, respectively). Patients with sNfL levels above the 99th percentile showed 
increased brain volume loss versus those with values below the 99th percentile (p<0.001 and 
p=0.003 for 2 and 5 years respectively; Supplementary Figure 6A and B). 
 
 
Figure 3. The estimated mean percentage of brain volume change in patients with sNfL above 
the respective age corrected percentiles gradually increased with increasing sNfL percentile 
category over 2 (A) and 5 years (B) of observation time. The mean reduction in spinal cord 
volume over 2 (C) and 5 years (D) gradually increased with increasing sNfL percentile 
category. For example, patients with sNfL above the 97.5th percentile had on average a 1.7% 
and 2.5% lower spinal cord volume at 2 (C) and 5 years (D) of follow-up as compared to those 
below the same percentile, respectively. Numbers in the figure denote the number of samples 
above or below the respective percentiles of healthy controls. 
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6. Association of sNfL with future spinal cord volume 
We also investigated the association between sNfL and the change in spinal cord volume over 
2 and 5 years of follow-up. A significant association between sNfL and the change in spinal 
cord volume over 2 and 5 years was present with an estimated additional average reduction in 
spinal cord volume of 0.19% over 2 years or 0.49% over 5 years per 10 pg/ml increase in sNfL 
(βadd=-0.191%, 95%CI=-0.295--0.086%, p<0.001, n=673 observations and βadd=-0.488%, 
95%CI=-0.783--0.192%, p=0.001, n=307 observations, respectively, Figure 4). The mean 
reduction in spinal cord volume over 2 and 5 years gradually increased with increasing sNfL 
percentile category (Figure 3C and D, Supplementary Table 8). For example, patients with sNfL 
above the 97.5th percentile as compared to those below the same percentile had on average a 
1.7% and 2.5% lower spinal cord volume at 2 and 5 years of follow-up respectively. Similarly, 
in progressive multiple sclerosis patients without contrast enhancing lesions over 2 and 5 years 
(n=161 and 61 observations, respectively), the mean reduction in spinal cord volume with sNfL 
above versus below the 95th (p=0.012 and 0.082, respectively), 97.5th (p=0.002 and 0.02) and 
99th (p=0.06 and <0.001) percentile gradually increased with increasing sNfL levels 
(Supplementary Figure 6C and D). 
 
 
Figure 4. A significant association between sNfL and the change in spinal cord volume over 5 
years was found with an estimated additional reduction in spinal cord volume of 0.49% over 5 
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years per 10 pg/ml increase in sNfL (βadd=-0.488%, 95%CI=-0.783--0.192%, p=0.001, n=307 
observations). 
 
Discussion  
There is an increasing interest in the potential use of sNfL as the first reliable blood-based 
marker of neuro-axonal damage in multiple sclerosis, as well as in other neurological 
conditions. Our study confirms in a large independent cohort our previous findings that sNfL 
levels in multiple sclerosis reflect the effect of ageing, recent relapses and concurrent disability 
(Disanto et al. 2017). We also provide new evidence that sNfL levels are increased in the 
presence of focal active inflammation, as measured by the number of brain contrast enhancing 
lesions and new or enlarging T2 lesions. We complemented our previous observation that the 
number of T2 lesions is associated with sNfL by showing that also T2 lesion volume, a more 
comprehensive measure of brain lesion burden is highly associated with sNfL. This finding 
further suggests that sNfL may be used to capture the extent of brain damage in individual 
patients. Importantly, we provide evidence that sNfL is also associated with the normalized 
brain volume at time of sampling. Taken together, these observations support that sNfL is a 
quantitative measure of the rate of neuronal loss within the central nervous system at the time 
of sampling. 
More relevant for the utility of sNfL as biomarker for individual decision making is its 
predictive power for the course of disease. We confirmed in this study that multiple sclerosis 
patients with higher sNfL levels are at higher risk of experiencing disability worsening in the 
following year (Disanto et al. 2017). We had previously reported an association between sNfL 
and brain atrophy over 2 years, but this study was limited by the small sample size (42 multiple 
sclerosis patients) and by the limited sensitivity of the assay used at that time (18% of samples 
being not reliably measurable) (Kuhle et al. 2017a). We now provide for the first time strong 
evidence that sNfL concentration is a predictor of brain atrophy in multiple sclerosis at 2 and 5 
years. Notably, when included in a multivariable model, sNfL remained significantly associated 
with future brain volume loss while T2 lesion volume, contrast enhancing lesions and baseline 
normalized brain volume did not. This suggests that sNfL can represent a more accurate 
indicator of ongoing neuro-axonal loss and a better predictor of brain atrophy than MRI 
measures of acute and chronic lesional activity. 
This is further reinforced by the novel finding of an association between sNfL and spinal cord 
atrophy. Noteworthy, sNfL levels were still associated with spinal cord volume change after 5 
years of follow-up. This observation is clinically relevant, given recent studies pointing at spinal 
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cord pathology as a key driver of long term disability accumulation in multiple sclerosis 
(Schlaeger et al. 2014;Zecca et al. 2016;Hagstrom et al. 2017). The fact that we were able to 
confirm the association of sNfL with spinal cord volume loss in the subgroup of progressive 
multiple sclerosis patients without detectable focal inflammatory MRI activity further 
underlines the independent contribution of sNfL as a prognostic marker of tissue damage. 
Taken together, these observations show that multiple sclerosis patients with higher sNfL levels 
are at higher risk of experiencing accelerated brain and spinal cord volume loss and worsening 
of disability scores in the long term. A practical implication of our findings is that patients with 
highest sNfL levels might be candidates for an escalation to more active treatments, to better 
prevent the occurrence and accumulation of further neuronal damage. 
Our study had some limitations. First, not all enrolled patients underwent MRI scans and 
atrophy measurements at 5 years. Although some patients were lost to follow-up in the setting 
of our prospective observational study, the loss of more active or more disabled participants 
would rather have reduced the power of our study to show significant correlations than biased 
the associations described. As our study was not designed to investigate treatment effects, it 
may not astonish that in this setting we did not replicate the negative association between sNfL 
levels and immunomodulating treatments described in our previous study (Disanto et al. 2017). 
Our failure to depict significant effects of treatment might be attributed to lower number of 
patients per treatment with variable follow-up and to the relative higher proportion of patients 
on first generation low efficacy drugs, most of these having started treatment already before 
inclusion in this study. For the study by Disanto et al., 2017 recruitment took place between 
2009 and 2016 and was focused on active patients starting or switching disease modifying 
therapies whereas patients in this study were recruited earlier (between 2004 and 2005), with 
limited access to the potentially more effective newer generation compounds. Ongoing or not 
yet fully published sNfL studies in the setting of randomized controlled trials are certainly much 
more appropriate to provide robust evidence that proves and quantifies potential treatment 
effects of currently available MS therapies on sNfL (Kuhle et al., 2016c; Kuhle et al., 2017b). 
The release of Neurofilament light chain into the peripheral blood represents a significant 
opportunity for monitoring disease activity and progression. A blood fluid biomarker has 
intrinsic characteristics such as providing a real-time signal covering the entirety of the CNS, 
lower cost and ability to measure repetitively in a non-invasive manner. The latter is also 
fundamental for the implementation of sNfL as an endpoint in clinical trials or routine clinical 
practice. The strong association with clinical relapses, disability scores, MRI measures of 
inflammation and with tissue damage in both brain and spinal cord, complemented by the 
 62 
 
intrinsic advantages of a peripheral body fluid biomarker, supports sNfL utility as a highly 
informative disease marker in multiple sclerosis. 
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Supplementary Material 
Cranial image acquisition and data analysis 
MRI analysis was performed centrally at the Medical Image Analysis Centre in Basel, blinded 
with respect to disease subtype, duration and treatment history. The measurement protocol 
included a three-dimensional T1-weighted scan (MPRAGE, TR/TI/TE/α = 2080 ms/1100 
ms/3.93 ms/15°; spatial resolution 0.98×0.98×1 mm3), a double-echo proton density/T2-
weighted sequence (TR/TE1/TE2 = 3980 ms/14 ms/108 ms; 0.98×0.98×3 mm3), and a T1-
weighted spin echo sequence (TR/TE = 552 ms/ 17 ms; 0.98×0.98×3 mm3). The latter was 
acquired for 5 min following administration of a single dose (0.1 mM/kg) of contrast agent. 
Qualitative analysis for the presence of gadolinium enhancement was performed on post-
contrast T1-weighted images. Brain lesions were identified and marked by consensus reading 
on simultaneously viewed T2-weighted and proton density-weighted images (Bendfeldt et al., 
2009). Additional evaluations were done for new T2 lesions, volume of T2 and T1 gadolinium 
enhanced lesions. The volumes were measured using an interactive digital analysis program 
(AMIRA 3.1.1; Mercury Computer System Inc). Brain atrophy was calculated on the 3D T1-
weighted data with SIENA (Structural Image Evaluation using Normalization of Atrophy) 
(Smith et al. 2001;Smith et al. 2002) between baseline and two-year follow-up, whereas long-
term atrophy was calculated between baseline and year five follow-up. SIENAX (an adaptation 
of SIENA for cross-sectional measurements), improved with lesion filling was used to estimate 
normalized brain volume (Battaglini et al. 2012;Smith et al. 2001;Smith et al. 2002). 
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Supplementary table 1 
Number of visits including serum samples and available MRI data. 
 Sum 
(n) 
BL Y1 Y2 Y3 Y4 Y5 Y6 Y7 Y8 Y9 Y10 
Visits 1684 257 240 205 179 167 151 143 123 98 93 28 
CEL 1190 257 238 201 110 126 135 118 5 0 0 0 
T2w lesion volume 1263 257 238 202 175 132 135 119 5 0 0 0 
New/enlarging T2w 964 - 238 199 173 125 112 112 5 0 0 0 
nBV 1130 256 237 199 174 132 132 0 0 0 0 0 
PBVC BL-Y2 197  - 197 - - - - - - - - 
PBVC BL-Y5 132  - - - - 132 - - - - - 
Spinal cord volume 1253 232 224 185 158 118 125 114 97 0 0 0 
BL: baseline; Y: year; CEL: contrast enhancing lesions; nBV: normalised brain volume; PBVC: percentage brain volume change.
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Supplementary table 2 
sNfL percentiles across different ages, derived from a Generalized Additive Model for 
Location, Scale, and Shape (GAMLSS) on sNfL in healthy controls (samples from baseline 
and one year follow-up). 
Age (years) 
sNfL percentiles (pg/ml) 
80th 90th 95th 97.5th 99th 
30 22.0 25.5 29.3 33.7 40.9 
35 24.6 28.5 32.7 37.6 45.7 
40 27.6 32.0 36.7 42.2 51.2 
45 31.0 35.9 41.3 47.4 57.5 
50 34.8 40.3 46.3 53.2 64.5 
55 38.8 44.9 51.6 59.3 71.9 
60 43.1 49.9 57.3 65.8 79.9 
65 47.6 55.1 63.2 72.7 88.2 
70 52.2 60.4 69.3 79.7 96.7 
sNfL: serum neurofilament light chain. 
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Supplementary table 3 
Demographics and clinical variables at baseline. 
Variables n (%) / median (IQR) 
Patients 257 
Age (years) 44.0 (36.2-53.2) 
Sex (females) 179 (69.6) 
Diagnosis at BL  
CIS* 11 (4.3) 
RRMS** 178 (69.3) 
SPMS 54 (21.0) 
PPMS 14 (5.4) 
Disease duration (years) 10.0 (5.0-18.0) 
EDSS 3.0 (2.0-4.0) 
Relapses year before BL  
0 182 (70.8) 
1 52 (20.2) 
2 23 (8.9) 
DMT at BL  
Untreated 91 (35.4) 
Interferon beta 1b 53 (20.6) 
Interferon beta 1a sc 40 (15.6) 
Glatirameracetate 33 (12.8) 
Interferon beta 1a im 24 (9.3) 
Mitoxantrone 7 (2.7) 
Azathioprin 6 (2.3) 
Other*** 3 (1.2) 
BL: baseline; CIS: clinically isolated syndrome; DMT: disease modifying treatment; EDSS: 
expanded disability status scale; im: intramuscular; IQR: interquartile range; PPMS: primary 
progressive multiple sclerosis; sc: subcutaneous; SPMS: secondary progressive multiple 
sclerosis. * 3 patients converted to RRMS during follow-up. ** 13 patients converted to 
SPMS during follow-up. *** Other: One patient on dimethyl-fumarate, and 2 patients on 
combination therapy of interferon beta 1b and azathioprin. 
 70 
 
Supplementary table 4  
Univariable and multivariable models testing associations between sNfL and age, sex, EDSS, disease course, recent relapses and DMT treatment 
status. 
Variables 
(1684 observations) 
sNfL (pg/ml),  
median, IQR  
Univariable Multivariable 
βmult 95%CI p βmult 95%CI p 
Age - 1.018 1.011-1.022 <0.001 1.015 1.011-1.020 <0.001 
Sex 
F (1140) 32.5 (21.8-45.9) - - - - - - 
M (544) 34.7 (25.0-48.3) 1.086 0.971-1.213 0.148 1.025 0.935-1.123 0.599 
Disease course 
RMS (1209) 29.7 (21.2-42.2) - - - - - - 
PMS (475) 41.9 (31.9-55.7) 1.312 1.198-1.436 <0.001 1.007 0.923-1.098 0.872 
EDSS - 1.094 1.070-1.120 <0.001 1.058 1.033-1.083 <0.001 
Recent relapse 
(<120 days) 
No (1545) 32.8 (23.2-45.9) - - - - - - 
Yes (139) 36.8 (24.1-56.3) 1.118 1.034-1.208 0.005 1.144 1.054-1.241 0.001 
DMT 
Treated 
(1169) 
33.3 (23.0-45.9) - - - - - - 
Untreated 
(515) 
32.4 (23.8-49.2) 0.926 0.851-1.008 0.075 0.953 0.885-1.028 0.215 
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Estimates (βmult) are multiplicative effects. sNfL: serum neurofilament light chain; CI: confidence interval; F: female; M: male; CIS: clinically 
isolated syndrome; RRMS: relapsing-remitting multiple sclerosis; PPMS: primary progressive multiple sclerosis; SPMS: secondary progressive 
multiple sclerosis; EDSS: Expanded Disability Status Scale; DMT: disease modifying treatment. 
 
Supplementary table 5  
Model-predicted marginal means and estimated odds ratio (βOR) including 95% confidence intervals from binominal GEE models: EDSS worsening 
between the current and subsequent visit (n=1401 observations). 
Percentile 
EDSS worsening between current and subsequent visit 
Samples (%) with 
sNfL > percentile 
Above (%, 95%CI) Below (%, 95%CI) βOR 95%CI p 
80th 642 (46) 14.1 (11.3-17.4) 9.6 (7.5-12.3) 1.539 1.07-2.22 0.021 
90th 432 (31) 16.4 (13.0-20.6) 9.6 (7.7-11.9) 1.858 1.32-2.63 <0.001 
95th 288 (21) 16.2 (12.4-21.0) 10.5 (8.6-12.7) 1.654 1.15-2.38 0.006 
97.5th 191 (14) 19.0 (14.1-25.1) 10.5 (8.6-12.6) 2.002 1.34-3.00 <0.001 
99th 112 (8) 20.7 (13.9-29.7) 10.9 (9.0-13.0) 2.143 1.27-3.61 0.004 
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Supplementary table 6 
Estimated percentage brain volume change over 2 years (βadd) in univariable and multivariable linear models testing for associations with baseline 
variables. 
Baseline variables 
(197 observations) 
Univariable Multivariable 
βadd (%) 95%CI (%) p βadd (%) 95%CI (%) p 
sNfL (per 10 pg/ml) -0.171 -0.226--0.116 <0.001 -0.134 -0.194--0.073 <0.001 
Age (years) -0.006 -0.021-0.009 0.453 0.005 -0.012-0.022 0.550 
Sex 
F (128) - - - - - - 
M (69) -0.162 -0.507-0.182 0.354 -0.084 -0.402-0.234 0.603 
EDSS  -0.165 -0.264--0.066 0.001 -0.151 -0.271--0.031 0.014 
Disease course 
RMS (147) - - - - - - 
PMS (50) -0.086 -0.464-0.292 0.654 0.357 -0.085-0.799 0.113 
T2 lesion vol. (per cm3) -0.042 -0.066--0.018 <0.001 -0.025 -0.051-0.002 0.071 
CEL -0.342 -0.499--0.0185 <0.001 -0.151 -0.313-0.010 0.067 
nBV (per 100 cm3) 0.201 0.039-0.363 0.015 0.016 -0.185-0.217 0.876 
Estimates (βadd) are additive effects. CEL: contrast enhancing lesions; CI: confidence interval; EDSS: Expanded Disability Status Scale; F: female; 
IQR: interquartile range; M: male; sNfL: serum neurofilament light chain. 
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Supplementary table 7 
Model-predicted marginal means and model estimates including 95% confidence intervals of the means from linear models: Estimated mean percent 
change in brain volume over A. 2 years (197 observations) and B. 5 years (132 observations).  
A. 
Percentiles 
Estimated mean percent change in brain volume (over 2 years) 
Samples n (%) with 
sNfL > percentile 
Above (%, 95%CI) Below (%, 95%CI) βadd (%) 95%CI p 
80th 103 (52) -1.21 (-1.43--0.99) -0.72 (-0.95--0.49) -0.49 -0.81--0.17 0.003 
90th 75 (38) -1.38 (-1.63--1.12) -0.73 (-0.93--0.53) -0.65 -0.98--0.33 <0.001 
95th 51 (26) -1.62 (-1.93--1.32) -0.75 (-0.93--0.57) -0.87 -1.23--0.52 <0.001 
97.5th 36 (18) -1.79 (-2.15--1.43) -0.79 (-0.96--0.62) -1.00 -1.40--0.60 <0.001 
99th 23 (12) -2.03 (-2.49--1.58) -0.83 (-1.00--0.67) -1.20 -1.68--0.72 <0.001 
B. 
Percentiles 
Estimated mean percent change in brain volume (over 5 years) 
Samples n (%) with 
sNfL > percentile 
Above (%, 95%CI) Below (%, 95%CI) βadd (%) 95%CI p 
80th 64 (49) -2.25 (-2.74--1.76) -1.46 (-1.83--1.10) -0.79 -1.40--0.18 0.011 
90th 48 (36) -2.53 (-3.13--1.94) -1.45 (-1.77--1.13) -1.08 -1.76--0.41 0.002 
95th 33 (25) -2.74 (-3.51--1.96) -1.55 (-1.85--1.24) -1.19 -2.02--0.36 0.005 
97.5th 20 (15) -3.14 (-4.29--1.99) -1.61 (-1.90--1.33) -1.53 -2.71--0.35 0.011 
99th 13 (10) -3.93 (-5.46--2.40) -1.62 (-1.89--1.35) -2.31 -3.87--0.76 0.004 
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Supplementary table 8 
Model-predicted marginal means and model estimates including 95% confidence intervals of the means from GEE models: Estimated mean percent 
change in spinal cord volume A. over 2 years (673 observations) and B. 5 years (307 observations). 
A. 
Percentiles 
Estimated mean change in spinal cord volume over 2 years 
Samples n (%) with 
sNfL > percentile 
Above (%, 95%CI) Below (%, 95%CI) βadd (%) 95%CI p 
80th 298 (44) -1.18 (-1.57--0.79) -0.41 (-0.65--0.17) -0.77 -1.19--0.35 <0.001 
90th 199 (30) -1.42 (-1.94--0.90) -0.47 (-0.72--0.23) -0.95 -1.52--0.37 0.001 
95th 133 (20) -1.85 (-2.54--1.16) -0.48 (-0.71--0.25) -1.37 -2.11--0.63 <0.001 
97.5th 87 (13) -2.27 (-3.22--1.31) -0.52 (-0.75--0.30) -1.74 -2.73--0.75 <0.001 
99th 47 (7) -2.28 (-3.58--0.98) -0.63 (-0.86--0.41) -1.65 -2.97--0.32 0.015 
B. 
Percentiles 
Estimated mean change in spinal cord volume over 5 years 
Samples n (%) with 
sNfL > percentile 
Above (%, 95%CI) Below (%, 95%CI) βadd (%) 95%CI p 
80th 131 (43) -2.60 (-3.52--1.69) -1.04 (-1.64--0.45) -1.56 -2.6--0.52 0.003 
90th 93 (30) -2.72 (-3.77--1.66) -1.28 (-1.82--0.74) -1.44 -2.5--0.38 0.008 
95th 64 (21) -3.11 (-4.47--1.74) -1.35 (-1.88--0.82) -1.75 -3.13--0.38 0.012 
97.5th 41 (13) -3.86 (-5.74--1.98) -1.39 (-1.90--0.88) -2.47 -4.33--0.61 0.009 
99th 23 (8) -5.84 (-8.64--3.05) -1.38 (-1.87--0.89) -4.47 -7.25--1.68 0.002 
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Supplementary figure 1 
Distribution of sNfL in the healthy controls with age based percentile curves. 
 
Legend: The distribution of serum NfL (sNfL) in healthy controls and its association with age 
was modelled by means of a Generalized Additive Models for Location, Scale, and Shape 
(GAMLSS) using a Box-Cox t distribution according to Rigby and Stasinopoulos (Rigby and 
Stasinopoulos, 2004) and cubic splines. From this model (n=484) percentile curves were 
obtained (please see the numerical values also in Supplementary Table 2). 
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Supplementary figure 2 
Treatments at respective study years/time periods separated by disease course (percentages). 
Left: Clinically Isolated Syndrome (CIS)/relapsing remitting MS (RRMS). Right: Primary 
progressive MS (PPMS)/ secondary progressive MS (SPMS). 
 
Low efficacy, first generation injectable drugs: interferon beta, glatiramer acetate 
Second generation oral compounds: Fingolimod, Dimethyl-fumarate, Teriflunomide 
High efficacy injectable monoclonal antibodies: Natalizumab, Rituximab 
Other: Mitoxantrone, Azathioprin, Interferon beta 1b (s.c.) plus azathioprin, Glatiramer acetate 
plus Mitoxantrone. 
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Supplementary figure 3 
Serum NfL concentrations in healthy controls, relapsing and progressive multiple sclerosis 
patients. 
 
 
 
Legend: After age correction both RMS (CIS/RRMS) and PMS (PPMS/SPMS) had higher 
sNfL than HC (RMS: 29.7 (21.2-42.2) pg/ml, βmult=1.263, 95%CI=1.179-1.353, p<0.001; PMS: 
41.9 (31.9-55.7) pg/ml, βmult=1.423, 95%CI=1.284-1.576, p<0.001). sNfL concentrations were 
also higher in PMS as compared to RMS (after age correction: βmult=1.154, 95%CI=1.059-
1.258, p=0.001). Numbers in the figure denote the number of samples. 
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Supplementary figure 4. 
Serum NfL concentrations and number of contrast enhancing lesions. 
 
Legend: Univariable analyses showed that sNfL levels were positively associated with the 
number of contrast enhancing lesions (βmult=1.174, 95%CI=1.105-1.246 per lesion, p<0.001, 
n=1190 observations). Numbers in the figure denote the number of samples. 
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Supplementary figure 5 
Serum NfL concentrations and number of new or enlarging T2 hyperintense lesions. 
 
 
Legend: Univariable analyses showed that sNfL levels were positively associated with the 
number of new or enlarging lesions (βmult=1.059, 95%CI=1.041-1.078 per lesion, p<0.001, 
n=964). Numbers in the figure denote the number of samples. 
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Supplementary figure 6. Estimated mean change in brain volume over 2 years (A) and 5 years (B) and spinal cord volume over 2 years (C) 
and 5 years (D) against sNfL dichotomized based on age corrected percentile curves from healthy controls in progressive multiple sclerosis 
patients without contrast enhancing lesions. 
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Legend: The mean estimated percentage of brain volume change in progressive multiple 
sclerosis patients without contrast enhancing lesions with sNfL above the 99th age corrected 
percentile was increased over 2 (A) and 5 years (B) of observation time. The mean reduction in 
spinal cord volume over 2 (C) and 5 years (D) gradually increased with increasing sNfL 
percentile category. The percentiles were constructed based on HC samples. Numbers in the 
figure denote the number of samples above or below the respective percentiles of healthy 
controls. 
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Chapter 4: Summary, discussion and future steps 
 
Currently no biomarker is supported by sufficient evidence to be used as a surrogate for clinical 
or MRI endpoints. Such biomarkers would need to be accurate and reproducible, to be 
associated with key clinical features and future outcome and, last but not least, to be derived 
from an easily accessible body fluid allowing repeated measurements over time. Particularly, 
biofluid markers bear the advantage of measuring ongoing pathologic changes real-time. 
Our aim was to develop and explore a highly sensitive biomarker of neuro-axonal damage in 
MS. The correlation of NfL concentrations in CSF with features of disease activity 
demonstrated was promising, however the relative invasiveness of lumbar punctures renders 
longitudinal CSF samplings impractical in routine clinical practice. On the other hand, 
quantitative analysis of the concentration of NfL in blood was below the sensitivity of existing 
technologies, given that physiological levels are 50-100 times lower than in CSF. Therefore, it 
was a primary aim to develop and analytically validate a NfL assay meeting this prerequisite 
by use of the 4th generation highly sensitive SIMOA platform2. 
In our first study, we showed that NfL can now be reliably measured in serum from MS patients 
using the SIMOA NfL assay developed during this PhD, even at very low concentration25,26. 
NfL levels in serum increased with age to a similar extent in both healthy controls (HC) and 
patient cohorts, while no difference was detected between genders. The age association has also 
been shown for CSF NfL measurements27 and we speculate that age related brain damage could 
be responsible for this observation. In this context, it would be important to investigate the 
impact of comorbidities and vascular risk factors on sNfL levels in both general and MS patient 
populations. The ability to measure NfL in blood samples is an important prerequisite to follow 
these questions in large enough and representative populations. 
As expected, we observed that NfL levels were considerably lower in serum than in paired CSF 
samples. However, there was a strikingly positive association between CSF NfL and sNfL, 
highlighting how serum levels directly reflect CSF NfL concentration. This suggests that 
neuronal death leads to the progressive release of neurofilaments in the extracellular space, CSF 
and blood, but how this exactly happens and the mechanisms involved and influencing the 
passage from CSF to blood are not known yet. For example, it would also be important to 
investigate the potential mechanisms influencing the molecules half life and influence of blood-
brain barrier integrity on the proportion of CSF NfL reaching the peripheral circulation. 
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Patients had higher sNfL concentration than healthy individuals confirming CSF NfL findings 
in MS9-11,28-33 and CIS34. Similarly to other neurological diseases including ALS, dementing 
illnesses and spinal cord injury20,35,36, we interpret these findings as a consequence of ongoing 
neuronal damage in the course of MS. This interpretation is further supported by the clear 
association between sNfL and both brain and spinal cord MRI lesions observed in our, as well 
as for CSF NfL in previously reported studies10,17,33,34,37.  
In longitudinal repeated measurements age, the presence of a recent relapses and neurological 
disability as measured by the EDSS were independently associated with levels of sNfL. 
Notably, sNfL levels were also significantly lower in DMT treated as compared to untreated 
patients, independently of all other variables. Also in the light of recent data resulting from 
sNfL analyses from plasma samples demonstrating treatment effects of fingolimod on NfL 
levels from a randomised controlled trial38, we believe that the associations of sNfL with DMT 
treatment status and time since treatment initiation strongly suggest that DMTs are able to 
reduce NfL release (as shown also for CSF NfL measurements for fingolimod, natalizumab and 
rituximab13,14,16-18,39,40). 
In the first study, we finally tested whether sNfL levels above age corrected percentiles derived 
from HC could predict clinically meaningful events in patients. We found that patients with 
sNfL levels above certain age adjusted sNfL percentiles derived from healthy controls have a 
progressively increased risk of both having experienced and experience in the future clinical 
relapses and disability accumulation. Similarly, the incidence of relapses in the following year 
and the risk of future EDSS worsening was higher in patients with sNfL values above versus 
below the respective normative percentiles. These findings suggest high sNfL could be used as 
an easily available indicator of recently developed neuronal damage, either in clinically silent 
status or when clinical changes are difficult to interpret and patients report symptoms that are 
not easily assessed with neurological examinations (e.g. increased fatigue, numbness, 
fluctuations of previously developed neurological signs or symptoms). They also support the 
potential use of sNfL as a prognostic marker for the future course of how severe the disease 
worsening. Two relatively small previous studies have shown that patients with higher CSF 
neurofilament levels have a worse disease outcome in the long term41,42. It is therefore plausible 
to see a similar association with sNfL and the easily availability of serum and the opportunity 
to perform repeated measurements in different phases of the disease and under different 
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treatments and various different treatment options with distinct efficacy versus risk profiles 
carry obvious and relevant clinical implications.  
In summary this study provided a number of important findings: sNfL levels i) can be reliably 
and reproducibly measured in serum samples from MS patients; ii) are positively associated 
with age but not gender in independent HC and MS cohorts; iii) closely correlate with NfL 
concentration in the CSF; iv) are increased in MS patients as compared to HC and positively 
associated with T2 and gadolinium enhancing lesions in both brain and spinal cord; v) are 
increased following relapses and in patients with higher EDSS scores, and decreased in DMT 
treated patients and after starting a new DMT; and vi) are associated with an increased risk of 
future relapses and EDSS worsening. 
In the second study we confirmed in an independent cohort our previous findings43 that age, 
recent relapses and concurrent disability are independently associated with sNfL levels in MS44. 
Importantly, sNfL levels were highly increased in the presence of brain CEL and independently 
associated with the overall T2 lesion volume and brain volume at time of sampling. These 
findings further supported the hypothesis that sNfL reflects the extent of neuronal loss within 
the CNS at the time of sampling. We also confirmed that MS patients with higher sNfL levels 
are at higher risk of experiencing disability worsening in the following year43 and for the first 
time we provided consistent evidence for sNfL concentration being a strong predictor of brain 
atrophy in MS at 2 and 5 years also in a multivariable analysis. Similar strong findings emerged 
when we analyzed the association between sNfL and spinal cord atrophy44. 
Taken together, these observations show how MS patients with higher sNfL concentrations are 
at increased risk of experiencing worsening in disability scores and higher rates of brain and 
spinal cord volume loss in the long term. We therefore believe these patients could benefit from 
an escalation to more active treatments, before the occurrence of irreversible neuronal damage. 
 
Ongoing and future research and Conclusions 
Meanwhile there is an established body of evidence that NfL levels may be decreased by 
effective DMT in MS, both based on measurement in serum38,43,45 and in CSF14,17,18. On the 
group level, levels of sNfL decrease typically within 3-6 months, but they do not reach age-
matched normal values, thus indicating persistence of continuous neuronal damage38,43. Many 
patients reach the status of NEDA (No Evidence of Disease Activity) or NEPAD (No Evidence 
of Progression or Active Disease) under DMT46, but a high proportion of individuals remain 
 85 
 
with high levels of NfL: 21.5% of the patients44 with NEDA had sNfL levels above the 90th 
age corrected percentile (unpublished). These data indicate that a high number of patients is not 
considered for appropriate therapy escalation, because they escape detection of subclinical 
disease activity based on current monitoring algorithms: here measurement of sNfL could be a 
sensitive therapy monitoring tool for the persistence of subclinical disease activity. 
Based on this, in a third and still ongoing study we hypothesized that sNfL will be suitable to 
monitor not only therapy response, but also the lack of it, and may guide physicians to modify 
therapy, despite the appearance that a patient may look to have clinically and radiologically 
‘silent’ disease. In a manuscript in preparation, we have investigated this hypothesis for 206 
patients under stable (3-24 months) therapy with fingolimod. Here, high levels of NfL occurred 
despite continuous fingolimod treatment and predicted quantitatively the risk for recurrence of 
relapse activity 1 (Figure 4A) or 2 years later (Figure 4B) and development of new T2 weighted 
lesions (Figure 4C), as well as the degree of annualized percentage brain volume loss (Figure 
4D) providing initial evidence for sNfL being useful to detect suboptimal treatment response in 
MS47. 
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Figure 4. Estimated annualised incidence risk ratios of the annualized relapse rate after one (A) 
and two (B) years of follow-up, annualized incidence risk ratios for new T2 lesions (C) and 
annualized brain volume change (D) against sNfL dichotomized based on age-corrected 
percentile curves from healthy controls. Numbers in the figure denote the number of samples 
above or below the respective percentiles of healthy controls (according to44). Abbreviations: 
ARR, annualized relapse rate; IRR, incidence rate ratio; PBVC, percentage brain volume 
change. Numbers in the graph denote the number of patients in each percentile category. 
 
Current evidence for the use of NfL as biomarker in MS is largely restricted to population-
based analyses and there are important gaps precluding its use in patient-by-patient based 
disease monitoring and individual therapeutic decision making48 that need to be overcome in 
the next years: 
i) NfL levels are independent of the molecular pathways of neuronal damage: for instance, 
in MS NfL levels cannot be used to differentiate between neuronal damage generated by acute 
(relapses) or chronic (progression) disease activity. The lack of knowledge on kinetics (turnover 
rate/half-life time) of NfL in blood circulation for both physiologic and disease conditions is 
the most prominent hurdle to better understand the relative contribution of each pathogenetic 
pathway (acute or chronic) to sustain the neurodegenerative process in MS; this is a current 
impediment for the use of NfL as predictive biomarker for progression, as well as for therapy 
monitoring49. 
ii) There is no normative data base available that allows to define individual values as being 
pathologic on the background of a physiologic 2.2%/year increase of levels between 18-70 
years43,44. 
iii) The impact of comorbidities on NfL levels in the context of its use as biomarker for MS 
needs to be further explored. Because NfL is such a sensitive measure, it reports on 'upstream' 
pathology and increases long before disease is manifest clinically50. Thus, the contribution of 
neurologic, psychiatric and non-communicable diseases needs to be factored into the 
assessment of sNfL levels. 
 
The successful closure of these gaps will be essential if sNfL levels are to be established as the 
first biofluid marker to quantify present and to predict future neurodegenerative processes in 
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MS, and to support therapeutic decision making in individual patients for personalised 
medicine. 
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